<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Retrovirology</journal-id><journal-id journal-id-type="iso-abbrev">Retrovirology</journal-id><journal-id journal-id-type="pmc-domain-id">244</journal-id><journal-id journal-id-type="pmc-domain">retrovir</journal-id><journal-title-group><journal-title>Retrovirology</journal-title></journal-title-group><issn pub-type="epub">1742-4690</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC5740944</article-id><article-id pub-id-type="pmcid-ver">PMC5740944.1</article-id><article-id pub-id-type="pmcaid">5740944</article-id><article-id pub-id-type="pmcaiid">5740944</article-id><article-id pub-id-type="pmid">29268769</article-id><article-id pub-id-type="doi">10.1186/s12977-017-0380-3</article-id><article-id pub-id-type="publisher-id">380</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Systems serology: profiling vaccine induced humoral immunity against HIV</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-0020-9704</contrib-id><name name-style="western"><surname>Chung</surname><given-names initials="AW">Amy W.</given-names></name><address><phone>+ 61 3 83449938</phone><email>awchung@unimelb.edu.au</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Alter</surname><given-names initials="G">Galit</given-names></name><address><phone>+1 857 268 7003</phone><email>galter@mgh.harvard.edu</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2179 088X</institution-id><institution-id institution-id-type="GRID">grid.1008.9</institution-id><institution>Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, </institution><institution>University of Melbourne, </institution></institution-wrap>792 Elizabeth St., Melbourne, VIC 3000 Australia </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0489 3491</institution-id><institution-id institution-id-type="GRID">grid.461656.6</institution-id><institution>Ragon Institute of MGH, MIT and Harvard University, </institution></institution-wrap>400 Technology Square, Cambridge, MA 02139 USA </aff></contrib-group><pub-date pub-type="epub"><day>21</day><month>12</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>14</volume><issue-id pub-id-type="pmc-issue-id">284321</issue-id><elocation-id>57</elocation-id><history><date date-type="received"><day>4</day><month>8</month><year>2017</year></date><date date-type="accepted"><day>27</day><month>11</month><year>2017</year></date></history><pub-history><event event-type="pmc-release"><date><day>21</day><month>12</month><year>2017</year></date></event><event event-type="pmc-live"><date><day>03</day><month>01</month><year>2018</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2020-02-06 14:56:26.777"><day>06</day><month>02</month><year>2020</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="12977_2017_Article_380.pdf"/><abstract id="Abs1"><p id="Par1">The results of the RV144 HIV vaccine, in combination with several recent non-human primate vaccine studies continue to highlight the potentially protective role of non-neutralizing Fc functional antibodies in HIV vaccine design. For many currently licensed vaccines, assays that detect antigen-specific antibody titers or neutralization levels have been used as a correlate of protection. However, antibodies can confer protection through multiple other mechanisms beyond neutralization, or mechanisms which are not dependent on total antibody titers. Alternative strategies that allow us to further understand the precise mechanisms by which antibodies confer protection against HIV and other infectious pathogens is vitally important for the development of future vaccines. Systems serology aims to comprehensively survey a diverse array of antibody features and functions, in order to simultaneously examine the mechanisms behind and distinguish the most important antibody features required for protection, thus identifying key targets for future experimental vaccine testing. This review will focus on the technical aspects required for the application of Systems serology and summarizes the recent advances provided by application of this systemic analytical approach.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Antibody</kwd><kwd>Systems serology</kwd><kwd>ADCC</kwd><kwd>IgG</kwd><kwd>Subclass</kwd><kwd>HIV</kwd><kwd>Vaccine</kwd><kwd>Fc effector function</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000925</institution-id><institution>National Health and Medical Research Council</institution></institution-wrap></funding-source></award-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001117</institution-id><institution>amfAR, The Foundation for AIDS Research</institution></institution-wrap></funding-source></award-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000060</institution-id><institution>National Institute of Allergy and Infectious Diseases</institution></institution-wrap></funding-source></award-group><award-group><funding-source><institution>Ragon Institute of MGH, MIT and Harvard University</institution></funding-source></award-group><award-group><funding-source><institution>NIH Harvard Center for AIDS Research</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction: Vaccine-induced humoral immunity</title><p id="Par2">Vaccines are one of the world&#8217;s most powerful public health interventions. Many of the currently licensed human vaccines are believed to confer protection through the induction of antigen-specific antibodies [<xref ref-type="bibr" rid="CR1">1</xref>]. These include vaccines against a range of viral pathogens such as hepatitis [<xref ref-type="bibr" rid="CR2">2</xref>], human papilloma virus [<xref ref-type="bibr" rid="CR3">3</xref>], polio [<xref ref-type="bibr" rid="CR4">4</xref>], influenza [<xref ref-type="bibr" rid="CR5">5</xref>] and yellow fever [<xref ref-type="bibr" rid="CR6">6</xref>], and the bacterial pathogens including pneumococcus [<xref ref-type="bibr" rid="CR7">7</xref>] and pertussis [<xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par3">The standard method of assessing vaccine-induced protective humoral immunity is through assays that detect either the level of antigen-specific antibody titres post vaccination, (typically via enzyme linked immunosorbent assays (ELISAs)), the quantity of &#8216;functional&#8217; antibody responses through inhibition of the pathogen or toxin (e.g. neutralization for polio virus, hemagglutination assay (HAI) for influenza) or opsonophagocytic activity (e.g. pneumococcal bacteria) [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. These conventional immunological methods are extremely valuable, as they are high throughput, easily standardizable, and thus will remain essential for evaluating vaccine responses. However, the caveat to many of these assays is that they measure a single or very limited number of humoral characteristics, and it is likely that other antibody-mediated mechanisms also contribute to protection against infection in vivo. For many infectious diseases, protection from or infection control is often observable in the absence of antibody neutralization. Instead, accumulating evidence across a spectrum of vaccines has suggested a critical role for additional, non-neutralizing, antibody functions, that is the ability of an antibody to interact with other immune components and effector cells via their Fc portions to mediate killing or control of the pathogen. These mechanism include, but are not limited to, antibody dependent cellular cytotoxicity (ADCC), antibody dependent cellular phagocytosis (ADCP), antibody dependent complement deposition in both protection from and control of HIV [<xref ref-type="bibr" rid="CR10">10</xref>&#8211;<xref ref-type="bibr" rid="CR13">13</xref>], influenza [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>], HSV [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>], Ebola virus [<xref ref-type="bibr" rid="CR18">18</xref>], and malaria [<xref ref-type="bibr" rid="CR19">19</xref>&#8211;<xref ref-type="bibr" rid="CR21">21</xref>]. Thus, alternative strategies that allow us to further understand and assess the precise mechanisms by which antibodies confer protection against pathogens is vitally important for the development and testing of future vaccines.</p></sec><sec id="Sec2"><title>HIV vaccines</title><p id="Par4">Three decades after the discovery of HIV, the journey towards the development of a protective HIV vaccine is still ongoing. While the overarching goal of an HIV antibody-based vaccine is to induce broadly neutralizing antibodies, this historically has not proven to be an easy feat [<xref ref-type="bibr" rid="CR22">22</xref>]. To date, there have only been four different HIV vaccine concepts that have been tested in a total of six human efficacy trials [<xref ref-type="bibr" rid="CR23">23</xref>]. Of these, the RV144 &#8216;Thai&#8217; Phase III trial was the first, and only, human HIV vaccine trial to demonstrate moderate efficacy (31.2%) [<xref ref-type="bibr" rid="CR24">24</xref>]. Surprisingly, this vaccine did not induce broadly neutralizing antibody responses. Instead non-neutralizing antibodies that recognize a specific region of the HIV Envelope (ENV) variable region 1 and 2 (V1V2) were associated with reduced risk of infection [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. Additional follow up analysis of the RV144 trial revealed that ADCC, antibody avidity to ENV and low tier neutralizing antibodies in the absence of IgA were secondary correlates of reduced risk of infection [<xref ref-type="bibr" rid="CR25">25</xref>].</p><p id="Par5">Based on these discoveries, a major focus of the HIV antibody vaccine field has been dedicated to understanding the functional role of these HIV-binding non-neutralizing antibodies [<xref ref-type="bibr" rid="CR27">27</xref>]. This has resulted in significant advancements in the technologies available to interrogate non-neutralizing functional antibody responses [<xref ref-type="bibr" rid="CR28">28</xref>]. It has also emphasized that assessing vaccine-induced humoral immune responses by quantifying the level of antigen-specific antibody titres alone is not a sufficient predictor of antibody protection or even Fc-effector functional capacity. Indeed, studies comparing the moderately protective RV144 vaccine trial [<xref ref-type="bibr" rid="CR24">24</xref>], consisting of ALVAC-HIV (vCP1521) prime and AIDSVAX B/E protein boosts, with its non-efficacious predecessor, VAX003 vaccine [<xref ref-type="bibr" rid="CR29">29</xref>], consisting of AIDSVAX B/E protein, revealed that VAX003 resulted in significantly higher total HIV-specific IgG levels compared to RV144 [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. However, the elevated levels of HIV-specific IgG induced by VAX003 were of a less functional nature, with elevated levels of poorly functional IgG4 subclass antibodies, that competed for antigen occupancy, thereby blocking Fc effector functions [<xref ref-type="bibr" rid="CR31">31</xref>]. In comparison, RV144 vaccination induced lower total HIV-specific IgG titers, but resulted in enhanced levels of highly functional IgG3 subclass antibodies that had the capacity to induce polyfunctional non-neutralizing responses including ADCC, ADCP and antibody-mediated activation of NK cells [<xref ref-type="bibr" rid="CR31">31</xref>]. These studies highlight the complexity of antibody interactions in vivo and suggest that broader Fc effector profiling and analytical methods may be required to objectively and comprehensively dissect vaccine induced Fc effector functions, in order to identify protective antibody immune features.</p></sec><sec id="Sec3"><title>Hierarchical layers of antibody features modulate Fc effector functions</title><p id="Par6">Upon vaccination, humoral diversification forms the foundation of the humoral immune response, that aims to target foreign antigen as broadly and effectively as possible [<xref ref-type="bibr" rid="CR32">32</xref>]. This response gives rise to polyclonal antibodies that are tuned by genetic, molecular and environmental factors to selectively respond in a pathogen-specific manner. The combined activity of these polyclonal pools is determined by a cumulative framework of antibody features; specificities dictated by the antibody Fragment antigen binding (Fab)&#160;region and Fc receptor binding capacity directed by the antibody Fragment crystalizable (Fc)&#160;region [<xref ref-type="bibr" rid="CR33">33</xref>]. For example, a subset of vaccine-induced antibodies may work in a cohesive, collaborative fashion, forming high avidity immune complexes with a preference towards activating Fc&#947; Receptor engagement and hence exhibiting a more functional Fc effector profile. However, a vaccine might also simultaneously induce antibodies with competing features, potentially blocking immune complex formation or reducing Fc&#947; Receptor engagement, thus potentially hindering Fc effector functions. Using the earlier described non-protective VAX003 vaccine as an example: VAX003 vaccination induced high levels of total HIV-specific IgG antibodies, however with proportionately elevated levels of weakly functional HIV-specific IgG4, that competed for antigen occupancy with more functional HIV-specific antibody subclasses (e.g. IgG1 and IgG3), overall resulting in a less functional immune response [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. However, depletion of IgG4 antibodies from IgG samples, resulted in significantly higher functional antibody responses [<xref ref-type="bibr" rid="CR31">31</xref>]. Similarly, depletion of the more functional HIV-specific IgG3 from vaccine samples resulted in a decrease in function. Thus collectively, functional antibody responses are the result of a dynamic equilibrium of the combination of these enhancing and competitive inhibitory antibody profiles, and the immune environment in which these antibodies are placed. Systems serology therefore aims to comprehensively examine as many of these antibody features as possible, in order to assess the mechanisms behind specific Fc&#160;effector responses and identify the most important antibody features required for superior Fc functional activity or protection induced by vaccination, pinpointing the key targets for future experimental validation and additional quantitative models.</p></sec><sec id="Sec4"><title>Systems serology</title><p id="Par7">Systems tools have revolutionized our understanding of basic immune processes including immune responses to vaccination, disease and immune development. Key to this developing area of research, is the comprehensive and unbiased collection of data to capture as much information as possible to inform and identify previously unappreciated processes in biology. This field has lead to the development of many OMIC tools including genomics (the whole molecular code) [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>], transcriptomics (the whole transcriptional code) [<xref ref-type="bibr" rid="CR36">36</xref>], proteomics (the building blocks and communicators within the system) [<xref ref-type="bibr" rid="CR37">37</xref>] and metabolomics (the nutritional/activity state of the system) [<xref ref-type="bibr" rid="CR38">38</xref>]. While all these tools provided deep information at the cellular level, they provided little resolution related to the humoral immune response, that is composed of polyclonal antibodies that can work together to modulate a range of different anti-pathogenic functions. Thus Systems serology was designed to address this area, with the specific aim to capture and assimilate as much information as possible related to the modulation of functional humoral immune responses.</p><p id="Par8">Systems serology consists of a fusion of high throughput experimental techniques aimed at dissecting the antibody features and functions, followed by a range of computational methods to help mine through and provide an unprecedented depth of understanding to the profiled antibodies. Simplistically, the experimental assays used to interrogate antibodies can be divided into (1<bold>)</bold>
<italic toggle="yes">Biophysical assays</italic> (Summarized in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>) and (2) <italic toggle="yes">Functional assays</italic> (Summarized in Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). <italic toggle="yes">Biophysical assays</italic> reflect the immediate genetic and molecular constraints of vaccine-induced antibodies that dictate antigen recognition and Fc&#947; Receptor engagement. In parallel, <italic toggle="yes">functional assays</italic> are used to examine, in vitro, the functional potential of these antibodies, which is dependent upon the availability of specific effector cells or immune environments. Upon compilation of these extensive datasets, both supervised and unsupervised machine learning <italic toggle="yes">computational techniques</italic>, commonly used in Systems biology, can be applied to allow for the examination of the multiple layers of antibody information, in order to help decipher and identify important features associated with protection and/or Fc functional activity.<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>Biophysical antibody profiles</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="8" rowspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d29e459" xlink:href="12977_2017_380_Figa_HTML.gif"/>
</th></tr><tr><th align="left" colspan="1" rowspan="1">Fragment</th><th align="left" colspan="3" rowspan="1">Fab</th><th align="left" colspan="5" rowspan="1">Fc</th></tr><tr><th align="left" colspan="1" rowspan="1">Feature</th><th align="left" colspan="1" rowspan="1">Antigen target</th><th align="left" colspan="1" rowspan="1">Epitope target</th><th align="left" colspan="1" rowspan="1">Antigen affinity</th><th align="left" colspan="1" rowspan="1">Isotype</th><th align="left" colspan="1" rowspan="1">Subclass</th><th align="left" colspan="1" rowspan="1">Glycans</th><th align="left" colspan="1" rowspan="1">FcR/C&#8217; binding</th><th align="left" colspan="1" rowspan="1">FcR affinity</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Examples of measurements</td><td align="left" colspan="1" rowspan="1">gp120 gp41<break/>p24</td><td align="left" colspan="1" rowspan="1">Scaffolds<break/>-V1V2<break/>-SOSIP<break/>-linear peptides</td><td align="left" colspan="1" rowspan="1">Dissociation constant<break/>(k-off)</td><td align="left" colspan="1" rowspan="1">IgA<break/>IgM<break/>IgG</td><td align="left" colspan="1" rowspan="1">IgG1<break/>IgG2<break/>IgG3<break/>IgG4<break/>IgA1<break/>IgA2</td><td align="left" colspan="1" rowspan="1">~30 glycan combinations<break/>Eg. Fucose, bisecting GLNAc, Galactose, Sialic Acid</td><td align="left" colspan="1" rowspan="1">C1q<break/>MBL<break/>Fc&#947;RI<break/>Fc&#947;RIIa<break/>Fc&#947;RIIb<break/>Fc&#947;RIIIa<break/>Fc&#947;RIIIb</td><td align="left" colspan="1" rowspan="1">Equilibrium constants (KD)</td></tr><tr><td align="left" colspan="1" rowspan="1">Examples of&#160;Assays</td><td align="left" colspan="1" rowspan="1">Multiplex<break/>ELISAs</td><td align="left" colspan="1" rowspan="1">Multiplex<break/>ELISAs<break/>ICS</td><td align="left" colspan="1" rowspan="1">SPR<break/>Chaotrope</td><td align="left" colspan="1" rowspan="1">Multiplex<break/>ELISAs</td><td align="left" colspan="1" rowspan="1">Multiplex<break/>ELISAs</td><td align="left" colspan="1" rowspan="1">Mass Spec<break/>HPLC<break/>CE<break/>Multiplex</td><td align="left" colspan="1" rowspan="1">ELISA<break/>Multiplex</td><td align="left" colspan="1" rowspan="1">SPR</td></tr><tr><td align="left" colspan="1" rowspan="1">References</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR104">104</xref>]</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR105">105</xref>]</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR104">104</xref>]</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR104">104</xref>]</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR87">87</xref>, <xref ref-type="bibr" rid="CR106">106</xref>]</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR87">87</xref>]</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR105">105</xref>, <xref ref-type="bibr" rid="CR107">107</xref>]</td></tr></tbody></table></table-wrap>
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table&#160;2</label><caption><p>Profiling functional Fc effector functions</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="6" rowspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d29e704" xlink:href="12977_2017_380_Figb_HTML.gif"/>
</th></tr><tr><th align="left" colspan="1" rowspan="1">Effector</th><th align="left" colspan="1" rowspan="1">Complement activation</th><th align="left" colspan="1" rowspan="1">ADCP</th><th align="left" colspan="1" rowspan="1">ADCC</th><th align="left" colspan="1" rowspan="1">Antibody dependent Cytokine secretion</th><th align="left" colspan="1" rowspan="1">Antibody dependent Chemokine secretion</th><th align="left" colspan="1" rowspan="1">Antibody dependent Virus Inhibition</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">NK cells</td><td align="left" colspan="1" rowspan="1">&#8722;</td><td align="left" colspan="1" rowspan="1">&#8722;</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+</td></tr><tr><td align="left" colspan="1" rowspan="1">Neutrophils</td><td align="left" colspan="1" rowspan="1">&#8722;</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">ND</td></tr><tr><td align="left" colspan="1" rowspan="1">Monocytes</td><td align="left" colspan="1" rowspan="1">&#8722;</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+</td></tr><tr><td align="left" colspan="1" rowspan="1">Dendritic cells</td><td align="left" colspan="1" rowspan="1">&#8722;</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">&#8722;</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">ND</td></tr><tr><td align="left" colspan="1" rowspan="1">Complement</td><td align="left" colspan="1" rowspan="1">+</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">+</td></tr><tr><td align="left" colspan="1" rowspan="1">Examples of&#160;Assays</td><td align="left" colspan="1" rowspan="1">Complement assay<break/>ELISA</td><td align="left" colspan="1" rowspan="1">Bead assay<break/>Virion assay</td><td align="left" colspan="1" rowspan="1">Cr51 Release<break/>RFADCC<break/>GranToxiLux<break/>Luciferase ADCC<break/>BVADCC</td><td align="left" colspan="1" rowspan="1">ICS</td><td align="left" colspan="1" rowspan="1">ICS</td><td align="left" colspan="1" rowspan="1">ADCVI</td></tr><tr><td align="left" colspan="1" rowspan="1">References</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR108">108</xref>]</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR109">109</xref>&#8211;<xref ref-type="bibr" rid="CR111">111</xref>]</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR112">112</xref>&#8211;<xref ref-type="bibr" rid="CR117">117</xref>]</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR118">118</xref>]</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR31">31</xref>]</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR13">13</xref>]</td></tr></tbody></table></table-wrap>
</p><sec id="Sec5"><title>Biophysical antibody features in HIV vaccines and infection</title><sec id="Sec6"><title>Antibody epitope recognition</title><p id="Par9">Vaccine-induced humoral immune responses can produce a multitude of polyclonal antibodies, that have the potential to target an extensive array of conformational and linear epitopes, which can be detected by multiple methods (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>&#8212;left columns). In the case of HIV vaccination, the required epitopes can be even more complex, as sequence variation across different strains and clades can alter not only epitope recognition but also ENV protein glycosylation patterns [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. In this context, the uniqueness and strength of functional Fc-mediated antibodies lies in their ability to target a large array of epitopes, beyond the few limited neutralizing antibody sites [<xref ref-type="bibr" rid="CR41">41</xref>], thus potentially allowing for the exploitation of alternative conserved sequences as epitopes [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. It is also due to the ability of non-neutralizing antibodies to target a diverse array of epitopes, that functional antibodies may potentially have greater breadth of recognition across different HIV clades [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>], an important measure to assess, due to the extreme diversity of HIV strains. Of interest, ADCC activity has also been observed against various other highly conserved HIV viral antigens including gag, pol and the accessory proteins, and has been linked to slower disease progression [<xref ref-type="bibr" rid="CR45">45</xref>&#8211;<xref ref-type="bibr" rid="CR47">47</xref>], however, due to the intracellular location of many of these epitopes, their relevance to protection from infection is still unclear. In addition to the nature of the epitope recognized, both the strength of antibody engagement with the antigen [<xref ref-type="bibr" rid="CR48">48</xref>] and epitope availability/masking can impact immune complex formation [<xref ref-type="bibr" rid="CR49">49</xref>]. Together, it can be hypothesized that higher affinity antibodies, recognizing readily available/conserved epitopes, will form prolonged immune complexes and hence have increased opportunities for Fc&#947; receptor engagement.</p></sec><sec id="Sec7"><title>Antibody Fc structure</title><p id="Par10">Despite its name, an antibody&#8217;s Fragment crystalizable (Fc), or constant region can also be highly modulated [<xref ref-type="bibr" rid="CR33">33</xref>]. These changes can influence an antibody&#8217;s ability to bind and engage Fc receptors present on innate immune cells or other immune components, such as complement. Binding ability can be modulated through small biophysical differences ranging from isotypes (e.g. IgG, IgA, IgM, IgE, IgD) or subclasses (e.g. IgG1-4) [<xref ref-type="bibr" rid="CR50">50</xref>], to single amino acid polymorphisms [<xref ref-type="bibr" rid="CR51">51</xref>], small glycan modifications [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR53">53</xref>] and immune complex size [<xref ref-type="bibr" rid="CR54">54</xref>], that collectively can contribute to differences in Fc&#8211;FcR binding ability. Several high throughput standardized assays have been developed to allow for the in-depth assessment for these features (Summarized in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>- right columns). In the context of HIV, multiple studies have demonstrated the importance of subclass, isotype and glycosylation state for control of disease and/or protection [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR55">55</xref>&#8211;<xref ref-type="bibr" rid="CR57">57</xref>]. For example, the results of the RV144 immune correlates analysis has suggested that serum IgA levels may be detrimental to vaccine efficacy [<xref ref-type="bibr" rid="CR25">25</xref>], potentially through competition of more functional vaccine-induced IgG, capable of mediated ADCC [<xref ref-type="bibr" rid="CR58">58</xref>]. However, in contrast, results from a non-human primate passive antibody immunization study, demonstrate that dimeric IgA1 was superior to both IgA2 and IgG1 in providing protection against SHIV mucosal infection [<xref ref-type="bibr" rid="CR59">59</xref>]. Overall these data suggest that IgA may have both protective and detrimental effects on HIV immunity, dependent on its location.</p></sec><sec id="Sec8"><title>Antibody dependent functional responses</title><p id="Par11">Prior to the results of the RV144 trial, the majority of functional Fc-mediated antibody research focused upon ADCC responses through assays that detected the lysis of target cells or inhibition of viral replication [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]. Many of the assays were highly complex, difficult to standardize, and time consuming, requiring the use of radioactive cells such as the chromium release assay or virus-infected primary target cells [<xref ref-type="bibr" rid="CR61">61</xref>]. However in the past decade, several high throughput ADCC and other functional Fc-mediated assays have been developed, allowing us to probe multiple other non-neutralizing antibody functions (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). These include, but are not limited to, antibody dependent complement dependent cytotoxicity (ADCDC) [<xref ref-type="bibr" rid="CR55">55</xref>], antibody dependent cellular (or viral) phagocytosis (ADCP) [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>], antibody mediated effector cell cytokine and chemokine secretion [<xref ref-type="bibr" rid="CR64">64</xref>] along with antibody dependent cellular viral inhibition (ADCVI) [<xref ref-type="bibr" rid="CR13">13</xref>]. Antibodies also have the capacity to induce multiple other effector functions including, but not limited to antibody dependent enzymatic release/respiratory burst [<xref ref-type="bibr" rid="CR21">21</xref>] and antibody mediated mucus trapping [<xref ref-type="bibr" rid="CR65">65</xref>]; however, high throughput qualitative robust assays to assess these functions in HIV are still in development.</p></sec><sec id="Sec9"><title>Fc&#947; receptor and effector cell diversity</title><p id="Par12">Fc-functional immune responses are often dictated by the innate immune effector cell that is being activated and its respective Fc&#947;R repertoire. It is for that reason that earlier ADCC studies commonly examined NK cell-specific antibody function, due to the fact that NK cells primarily express a single activating Fc&#947;RIIIa (CD16a) allowing for easier interpretation of results [<xref ref-type="bibr" rid="CR66">66</xref>]. However, three distinct classes of Fc&#947;Rs are expressed on human innate immune cells, with varying levels of expression dependent on cell type. These include Fc&#947;RI, Fc&#947;IIa/b/c, and Fc&#947;IIIa/b, which bind the different IgG subclasses with varying proficiency, and can cause either activation or inhibition of the effector cell [<xref ref-type="bibr" rid="CR50">50</xref>]. Furthermore, a range of Fc&#947;R polymorphisms have been identified in humans, some of which have greater Fc binding affinity and hence are associated with enhanced Fc effector functional capacity. For example, individuals carrying the high affinity Fc&#947;RIIa H131 polymorphism, most commonly associated with enhanced ADCP, have positive outcomes in both cancer [<xref ref-type="bibr" rid="CR67">67</xref>] and infectious disease studies, including HIV [<xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR69">69</xref>]. In contrast, the Fc&#947;RIIIa V158 polymorphism, associated with enhanced ADCC functionality, has been linked with better outcomes within the monoclonal therapeutics cancer field [<xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR71">71</xref>]. Conversely, however, this same polymorphism has been associated with HIV disease progression [<xref ref-type="bibr" rid="CR72">72</xref>] and the lack of protection from the VAX004 vaccine trial [<xref ref-type="bibr" rid="CR73">73</xref>]. Thus assays able to capture the functional activity of antibodies through multiple Fc&#947;Rs may provide enhanced resolution of the vast repertoire of functions that may be leveraged to control/kill HIV, while assays utilizing individual Fc&#947;Rs provide an opportunity to critically capture a quantitative view of a specific antibody function. Furthermore, Fc&#947;R expression profiles may change with infection status and site of infection [<xref ref-type="bibr" rid="CR74">74</xref>], all which must be considered in the process of establishing meaningful assays for the analysis of functional humoral immune responses, as these Fc&#947;Rs compete on the surface of innate immune cells for immune complex binding. For many of the described Fc effector assays, specific Fc&#947;R bearing innate immune cells can be isolated and their Fc&#947;R polymorphisms and expression levels can be determined, so that the Fc-mediated immune responses can examined and later reconstituted in a biologically meaningful manner.</p></sec><sec id="Sec10"><title>Assay selection and technical considerations</title><p id="Par13">As with all experimental assays, standardization and optimization is critical to enable accurate cross-study comparisons. Control samples are essential for validation and quality control. Furthermore, sample and control replicates should be completed for all assays to confirm assay reliability, and data accuracy. Data analysis techniques can be utilized to confirm assay and data quality, these include determining signal to noise ratios or calculating the Z score [<xref ref-type="bibr" rid="CR75">75</xref>].</p><p id="Par14">It is important to note that a more robust, optimized assay does not necessarily reflect biological relevance. For example many of the most reproducible functional antibody assays utilize cell lines that are representative of functional immune responses [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR76">76</xref>]. There are multiple advantages to these assays including high throughput data quality and repeatability on an intra-laboratory basis. However it should be acknowledged that they often do not represent the biological diversity as observed when using assays that utilize primary cells [<xref ref-type="bibr" rid="CR77">77</xref>]. In contrast, assays that involve the isolation and use of primary Fc&#947;R receptor cells, especially from mucosal tissues to assess for functional humoral responses, may be highly biologically relevant, however currently, robust high throughput technologies with the capacity to assess these responses are less developed. Thus assay selection may also take into consideration current assay technology constraints and biological significance.</p><p id="Par15">The full spectrum of biophysical and functional assays should ideally be collected from all samples, thus allowing for a sweeping assessment and the application of computational approaches to the entire cohort. While admittedly it is not always feasible or practical to collect entire data sets from large cohorts, estimating smaller sample sizes for reliable analysis should be carefully considered prior to experimental data collection, as this can be influenced by multiple factors, including the computational methods applied and dimensionality of the data (e.g. number antibody features and functions) [<xref ref-type="bibr" rid="CR78">78</xref>].</p></sec><sec id="Sec11"><title>Computational techniques</title><p id="Par16">When all measurements are compiled, systems-level computational analysis can then be applied to probe for mechanistic insights or antibody biomarkers of protection. A variety of different &#8220;<italic toggle="yes">machine learning</italic>&#8221; or data-driven computational approaches have been previously applied to Systems biology and Systems vaccinology (reviewed [<xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR80">80</xref>]) and more recently Systems serology [<xref ref-type="bibr" rid="CR81">81</xref>]. These approaches are broadly classified as &#8216;<italic toggle="yes">unsupervised</italic>&#8217; and &#8216;<italic toggle="yes">supervised</italic>&#8217; approaches. &#8216;<italic toggle="yes">Unsupervised</italic>&#8217; approaches explore the compiled datasets, without predefining groups to base the analysis upon, thus allowing for the identification of natural similarities or &#8220;clusters&#8221; within the data. A major advantage of unsupervised systemic examination of broad Fc effector profiles, is the ability to comprehensively explore the mechanisms behind specific functions or correlates of protection in an unbiased fashion, potentially revealing novel linkages that would not normally be identified by traditional approaches. Previous unsupervised approaches that have been successfully applied in Systems serology research include principal component analysis (PCA) and correlation networks [<xref ref-type="bibr" rid="CR82">82</xref>&#8211;<xref ref-type="bibr" rid="CR84">84</xref>].</p><p id="Par17">In contrast, &#8216;<italic toggle="yes">supervised</italic>&#8217; approaches include the addition of predefined groups or classifications, from which the analysis is based, with the goal of identifying key parameters associated with the predefined groups or &#8220;classes&#8221;. In the context of Systems serology, these groups may be related to a specific advantageous Fc effector function (e.g. ADCC or ADCP etc.) or clinical outcome (e.g. protective versus non-protective vaccine), with the aim to identify novel correlates of protection or key antibody features associated with Fc effector functions. Supervised analytical techniques that have previously been applied to Systems serology include partial least squares discriminant analysis (PLSDA) and decision tree analyses [<xref ref-type="bibr" rid="CR82">82</xref>, <xref ref-type="bibr" rid="CR84">84</xref>&#8211;<xref ref-type="bibr" rid="CR86">86</xref>].</p><p id="Par18">In addition, current high throughput assays used to measure antibody structure and function can generate tens and more often&#160;hundreds of data points per sample (for example, Fc/isotype multiplex arrays or peptide epitope mapping) [<xref ref-type="bibr" rid="CR87">87</xref>]. The strength of this comprehensive approach is that all samples are assessed in an unbiased manner for as many functional antibody features as possible. The downside of this analysis is that many of these antibody features and functions have the potential to be highly correlated with each other, thus highlighting multiple features and often resulting in over complex models. This can create overwhelmingly large data sets, where the total number of antibody measurements can outweigh the number of samples tested. Thus feature selection methods are useful for minimizing the number of selected features, correcting for the effect of over fitting data, which can improve model performance and help reduce complexity of the data (reviewed in [<xref ref-type="bibr" rid="CR88">88</xref>, <xref ref-type="bibr" rid="CR89">89</xref>]).</p><p id="Par19">Overall, application of these machine learning computational techniques in Systems serology research, has the ability to highlight the most critical associations between antibody features and functions with protection from HIV infection, thus becoming a highly targeted and comprehensive hypothesis driving tool that can accelerate our understanding of the humoral immune system, and help to identify key areas of interest for further experimentation, vaccine testing or exploration by additional quantitative models.</p></sec></sec><sec id="Sec12"><title>Systems approaches for the analysis of functional antibody responses in human vaccination</title><p id="Par20">Previous application of Systems biology and vaccinology approaches has resulted in the identification of genetic or immune signatures that correlate with vaccine efficacy for yellow fever [<xref ref-type="bibr" rid="CR90">90</xref>], influenza [<xref ref-type="bibr" rid="CR91">91</xref>] and malaria [<xref ref-type="bibr" rid="CR92">92</xref>, <xref ref-type="bibr" rid="CR93">93</xref>]. These predictive signatures can be used to identify novel mechanistic insights and aid the development of future vaccine strategies, while also serving as valuable biomarkers to screen for vaccine efficacy in future trials.</p><p id="Par21">In our application of Systems serology to different human HIV vaccines [<xref ref-type="bibr" rid="CR84">84</xref>], we utilized a variety of modelling and data clustering techniques to examine the antibody profiles of the moderately protective RV144 trial (ALVAC and AIDSVAX B/E [<xref ref-type="bibr" rid="CR24">24</xref>]) and two non-efficacious HIV vaccine trials: VAX003 (AIDSVAX B/E [<xref ref-type="bibr" rid="CR29">29</xref>]); and HVTN204 (DNA/rAD5 [<xref ref-type="bibr" rid="CR94">94</xref>]). Importantly, application of both unsupervised and supervised analysis approaches were able to differentiate between AIDSVAX B/E protein containing vaccines (i.e. RV144 and VAX003) and DNA/rAD5 vaccination (HVTN204). Furthermore, in a supervised analysis that applied LASSO [<xref ref-type="bibr" rid="CR95">95</xref>] (least absolute feature shrinkage and selection operator) for feature selection followed by PLSDA [<xref ref-type="bibr" rid="CR96">96</xref>] (partial least-squares discriminant analysis), we were able to clearly differentiate between RV144 and the non-efficacious VAX003 trial samples, reconfirming previous studies that associated RV144 with enhanced levels of IgG3 and VAX003 with an elevated IgG4 signature [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>].</p><p id="Par22">A similar supervised LASSO and PLSDA approach was applied to RV144 recipients separated into those with high or low V1V2 responses, as a representation of low versus high risk of infection, based on the original immune correlate analysis [<xref ref-type="bibr" rid="CR25">25</xref>]. High IgG V1V2 responder profiles, with predicted low risk of infection, were associated with high levels of HIV-specific IgG1 along with multiple or potentially &#8220;polyfunctional&#8221; Fc effector functions including ADCP, ADCC, and antibody dependent NK cell activation. Follow up studies now also suggest that high V1V2 responders not only have enhanced Fc functionality, but may also have increased ADCC epitope breadth [<xref ref-type="bibr" rid="CR44">44</xref>]. In contrast, low IgG V1V2 responders, predicted to have a higher risk of infection, were associated with HIV-specific IgA, recapitulating earlier immune correlate studies [<xref ref-type="bibr" rid="CR25">25</xref>]. Of interest, repetition of this analysis comparing high and low IgG3-V1V2 responders (which was also detected to be a correlate of protection [<xref ref-type="bibr" rid="CR30">30</xref>]), associated high IgG3-V1V2 responders with activating Fc&#947;RIIa, required for ADCP, and Fc&#947;RIIIa, which is critical for NK cell activation and ADCC. These results reinforce the importance of polyfunctional Fc-effector functions. However, contrary to the total IgG-V1V2 analysis, IgA was not identified as a correlate of the low IgG3 V1V2 responder profile, suggesting that IgA responses may exert varying degrees of modulation/interference with Fc effector responses. Further studies to dissect the divergent roles of IgA, potentially in a V1V2 subclass specific manner, may be warranted.</p><p id="Par23">Functional humoral immune responses are induced through the engagement of immune complexes that consist of varying antibody composition, antigen specificity and Fc&#947;R engagement. Thus the interactions required for Fc functions are an ideal model for the application of network and pathway analyses that are commonly applied in bioinformatics analyses (reviewed in [<xref ref-type="bibr" rid="CR97">97</xref>, <xref ref-type="bibr" rid="CR98">98</xref>]). These approaches are useful as they allows us to simultaneously examine the connectivity between different antibody functions and features to examine mechanisms behind antibody functional activity, in an unbiased, objective manner. These interactions are often displayed as networks that illustrate the degree of connectivity between different features. Examination of the structural organization and topology of these biological networks can provide us with information behind key interactions that regulate a specific functional immune response. Application of correlation networks analysis to the different vaccine trials revealed extremely different network topographies or &#8216;humoral fingerprints&#8217;. Importantly the connectivity analysis using RV144 samples reiterated earlier PLSDA results, demonstrating that ENV-specific IgG1 and IgG3 responses were interconnected with multiple antibody effector functions including ADCC, ADCP and ADCDC, which was not observed for the other non-efficacious vaccine trials.</p></sec></sec><sec id="Sec13"><title>Systems serology approaches in non-human primate models efficacy trials</title><p id="Par24">Similar Systems serology approaches have also been applied to several SIV and SHIV vaccine trials [<xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR99">99</xref>, <xref ref-type="bibr" rid="CR100">100</xref>]. A combination of Systems biology and Systems serology analyses was applied to a non-human primate (NHP) RV144-like vaccine and challenge study consisting of an ALVAC prime followed gp120 protein boost vaccine strategy, comparing the adjuvants Alum and MF-59. Systems analysis of this study was able to associate mucosal innate lymphoid cells producing IL-17, RAS activation, and mucosal V2 antibodies with delayed acquisition of infection [<xref ref-type="bibr" rid="CR100">100</xref>]. A second NHP vaccine study, consisting of Ad26 prime followed by ENV protein boost, applied similar systems serology techniques and associated the observed 50% protection from repeated SIV challenges with polyfunctional Fc effector functions including ADCP, ADCC, ADCD and antibody mediated NK cell activation [<xref ref-type="bibr" rid="CR86">86</xref>]. Collectively, these NHP systems serology studies reinforce the results of the previous RV144 immune correlates analysis [<xref ref-type="bibr" rid="CR25">25</xref>] and in combination with the RV144 Systems serology study [<xref ref-type="bibr" rid="CR84">84</xref>], suggest that future HIV vaccines capable of eliciting polyfunctional Fc effector profiles, with a preferential upregulation of IgG3 subclasses and high levels of V2 antibodies may be able to reduce the risk of HIV infection.</p><p id="Par25">In the future, additional Systems serology analysis of vaccine trials in NHP, with known efficacy will provide us additional opportunities to identify correlates of protection. Importantly, NHP vaccine trials provide us with the unique opportunity to dissect responses to a deeper degree, often not possible in human vaccination, both by way of sample collection and information about the challenge virus [<xref ref-type="bibr" rid="CR101">101</xref>]. While there are significant differences in both Fc&#947;R and IgG biology between humans and NHP, dissecting the NHP Fc&#947;R and Immunoglobulin H locus is an area of growing intense research [<xref ref-type="bibr" rid="CR102">102</xref>]. As our understanding of this field grows, we may be able to better build parallels between NHP and human protective responses that will allow us to build predictive models that may help guide the HIV vaccine field.</p></sec><sec id="Sec14"><title>Systems serology: A constantly expanding platform</title><p id="Par26">It is important to note that the technologies available to measure biophysical antibody features and functions are constantly evolving to allow for the assessment of more diverse cell types, cellular environments, receptors and antigen specificities. No doubt, in the future, many other high throughput assays will be developed to allow for advanced measurements of antibody features. Next-generation sequencing and bioinformatics have already enabled probing of the antibody repertoire and greater understanding of the evolution of broadly neutralizing antibodies, and these techniques could be modified and applied to explore the evolution of polyfunctional non-neutralizing or V1V2 antibodies [<xref ref-type="bibr" rid="CR103">103</xref>]. Similarly, new technologies are being developed to better examine mucosal antibody features, as well as functional assays that better represent in vivo Fc-functional responses from different effector sites such as blood, gut, and reproductive mucosal environments. Additionally, a multitude of alternative analytical approaches could be applied to qualitatively evaluate vaccines responses. Application of Systems serology is not limited to HIV vaccinology, but could potentially be applied to numerous other infectious and autoimmune diseases [<xref ref-type="bibr" rid="CR83">83</xref>], or could be used to examine differences in humoral immune responses amongst individuals of differing gender, age or ethnicity. There is no doubt that Systems serology is still in its early developmental stages and will continue to evolve over time to capture broader Fc-effector profiling and improved multi-dimensional analytic approaches, providing us with an increasingly comprehensive understanding of the humoral immune response required for the identification of the most desirable vaccine profiles in order to guide the rational design of future HIV vaccine candidates.</p></sec></body><back><ack><title>Authors&#8217; contributions</title><p>AWC and GA prepared and edited the manuscript. Both authors read and approved the final manuscript.</p><sec id="FPar1"><title>Acknowledgements</title><p id="Par27">We are grateful to Dr. Jennifer Juno and Prof Stephen Kent for their support and comments.</p></sec><sec id="FPar2"><title>Competing interests</title><p id="Par28">The authors declare that they have no competing interests.</p></sec><sec id="FPar3"><title>Availability of data and materials</title><p id="Par29">Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.</p></sec><sec id="FPar4"><title>Funding</title><p id="Par30">This work was supported by the Australian National Health &amp; Medical Research Center (AWC), the American Foundation for AIDS Research (amfAR) Mathilde Krim Fellowship (AWC), the Bill and Melinda Gates Foundation (GA), NIAID (GA), the Ragon Institute (GA), and NIH Harvard Center for AIDS Research (GA).</p></sec><sec id="FPar5"><title>Publisher&#8217;s Note</title><p id="Par31">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Plotkin</surname><given-names>SA</given-names></name></person-group><article-title>Correlates of protection induced by vaccination</article-title><source>Clin Vaccine Immunol</source><year>2010</year><volume>17</volume><fpage>1055</fpage><lpage>1065</lpage><pub-id pub-id-type="doi">10.1128/CVI.00131-10</pub-id><pub-id pub-id-type="pmid">20463105</pub-id><pub-id pub-id-type="pmcid">PMC2897268</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>AD</given-names></name><name name-style="western"><surname>Hall</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Maine</surname><given-names>N</given-names></name><name name-style="western"><surname>Mendy</surname><given-names>M</given-names></name><name name-style="western"><surname>Whittle</surname><given-names>HC</given-names></name></person-group><article-title>What level of hepatitis B antibody is protective?</article-title><source>J Infect Dis</source><year>1999</year><volume>179</volume><fpage>489</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1086/314578</pub-id><pub-id pub-id-type="pmid">9878036</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frazer</surname><given-names>I</given-names></name></person-group><article-title>Correlating immunity with protection for HPV infection</article-title><source>Int J Infect Dis</source><year>2007</year><volume>11</volume><issue>Suppl 2</issue><fpage>S10</fpage><lpage>S16</lpage><pub-id pub-id-type="doi">10.1016/S1201-9712(07)60016-2</pub-id><pub-id pub-id-type="pmid">18162240</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Faden</surname><given-names>H</given-names></name><name name-style="western"><surname>Modlin</surname><given-names>JF</given-names></name><name name-style="western"><surname>Thoms</surname><given-names>ML</given-names></name><name name-style="western"><surname>McBean</surname><given-names>AM</given-names></name><name name-style="western"><surname>Ferdon</surname><given-names>MB</given-names></name><name name-style="western"><surname>Ogra</surname><given-names>PL</given-names></name></person-group><article-title>Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses</article-title><source>J Infect Dis</source><year>1990</year><volume>162</volume><fpage>1291</fpage><lpage>1297</lpage><pub-id pub-id-type="doi">10.1093/infdis/162.6.1291</pub-id><pub-id pub-id-type="pmid">2172403</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wheatley</surname><given-names>AK</given-names></name><name name-style="western"><surname>Kent</surname><given-names>SJ</given-names></name></person-group><article-title>Prospects for antibody-based universal influenza vaccines in the context of widespread pre-existing immunity</article-title><source>Expert Rev Vaccines</source><year>2015</year><volume>14</volume><fpage>1227</fpage><lpage>1239</lpage><pub-id pub-id-type="doi">10.1586/14760584.2015.1068125</pub-id><pub-id pub-id-type="pmid">26175180</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mason</surname><given-names>RA</given-names></name><name name-style="western"><surname>Tauraso</surname><given-names>NM</given-names></name><name name-style="western"><surname>Spertzel</surname><given-names>RO</given-names></name><name name-style="western"><surname>Ginn</surname><given-names>RK</given-names></name></person-group><article-title>Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine</article-title><source>Appl Microbiol</source><year>1973</year><volume>25</volume><fpage>539</fpage><lpage>544</lpage><pub-id pub-id-type="pmid">4633476</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/am.25.4.539-544.1973</pub-id><pub-id pub-id-type="pmcid">PMC380857</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>LH</given-names></name><name name-style="western"><surname>Frasch</surname><given-names>CE</given-names></name><name name-style="western"><surname>Falk</surname><given-names>LA</given-names></name><name name-style="western"><surname>Klein</surname><given-names>DL</given-names></name><name name-style="western"><surname>Deal</surname><given-names>CD</given-names></name></person-group><article-title>Correlates of immunity for pneumococcal conjugate vaccines</article-title><source>Vaccine</source><year>2003</year><volume>21</volume><fpage>2190</fpage><lpage>2196</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(03)00025-2</pub-id><pub-id pub-id-type="pmid">12706710</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kilgore</surname><given-names>PE</given-names></name><name name-style="western"><surname>Salim</surname><given-names>AM</given-names></name><name name-style="western"><surname>Zervos</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Schmitt</surname><given-names>HJ</given-names></name></person-group><article-title>Pertussis: microbiology, disease, treatment, and prevention</article-title><source>Clin Microbiol Rev</source><year>2016</year><volume>29</volume><fpage>449</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1128/CMR.00083-15</pub-id><pub-id pub-id-type="pmid">27029594</pub-id><pub-id pub-id-type="pmcid">PMC4861987</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pulendran</surname><given-names>B</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>R</given-names></name></person-group><article-title>Immunological mechanisms of vaccination</article-title><source>Nat Immunol</source><year>2011</year><volume>12</volume><fpage>509</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1038/ni.2039</pub-id><pub-id pub-id-type="pmid">21739679</pub-id><pub-id pub-id-type="pmcid">PMC3253344</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hessell</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Hangartner</surname><given-names>L</given-names></name><name name-style="western"><surname>Hunter</surname><given-names>M</given-names></name><name name-style="western"><surname>Havenith</surname><given-names>CE</given-names></name><name name-style="western"><surname>Beurskens</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Bakker</surname><given-names>JM</given-names></name><name name-style="western"><surname>Lanigan</surname><given-names>CM</given-names></name><name name-style="western"><surname>Landucci</surname><given-names>G</given-names></name><name name-style="western"><surname>Forthal</surname><given-names>DN</given-names></name><name name-style="western"><surname>Parren</surname><given-names>PW</given-names></name><etal/></person-group><article-title>Fc receptor but not complement binding is important in antibody protection against HIV</article-title><source>Nature</source><year>2007</year><volume>449</volume><fpage>101</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1038/nature06106</pub-id><pub-id pub-id-type="pmid">17805298</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barouch</surname><given-names>DH</given-names></name><name name-style="western"><surname>Stephenson</surname><given-names>KE</given-names></name><name name-style="western"><surname>Borducchi</surname><given-names>EN</given-names></name><name name-style="western"><surname>Smith</surname><given-names>K</given-names></name><name name-style="western"><surname>Stanley</surname><given-names>K</given-names></name><name name-style="western"><surname>McNally</surname><given-names>AG</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Abbink</surname><given-names>P</given-names></name><name name-style="western"><surname>Maxfield</surname><given-names>LF</given-names></name><name name-style="western"><surname>Seaman</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys</article-title><source>Cell</source><year>2013</year><volume>155</volume><fpage>531</fpage><lpage>539</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.09.061</pub-id><pub-id pub-id-type="pmid">24243013</pub-id><pub-id pub-id-type="pmcid">PMC3846288</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bournazos</surname><given-names>S</given-names></name><name name-style="western"><surname>Klein</surname><given-names>F</given-names></name><name name-style="western"><surname>Pietzsch</surname><given-names>J</given-names></name><name name-style="western"><surname>Seaman</surname><given-names>MS</given-names></name><name name-style="western"><surname>Nussenzweig</surname><given-names>MC</given-names></name><name name-style="western"><surname>Ravetch</surname><given-names>JV</given-names></name></person-group><article-title>Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity</article-title><source>Cell</source><year>2014</year><volume>158</volume><fpage>1243</fpage><lpage>1253</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.08.023</pub-id><pub-id pub-id-type="pmid">25215485</pub-id><pub-id pub-id-type="pmcid">PMC4167398</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forthal</surname><given-names>DN</given-names></name><name name-style="western"><surname>Landucci</surname><given-names>G</given-names></name><name name-style="western"><surname>Daar</surname><given-names>ES</given-names></name></person-group><article-title>Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells</article-title><source>J Virol</source><year>2001</year><volume>75</volume><fpage>6953</fpage><lpage>6961</lpage><pub-id pub-id-type="doi">10.1128/JVI.75.15.6953-6961.2001</pub-id><pub-id pub-id-type="pmid">11435575</pub-id><pub-id pub-id-type="pmcid">PMC114423</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DiLillo</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Tan</surname><given-names>GS</given-names></name><name name-style="western"><surname>Palese</surname><given-names>P</given-names></name><name name-style="western"><surname>Ravetch</surname><given-names>JV</given-names></name></person-group><article-title>Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo</article-title><source>Nat Med</source><year>2014</year><volume>20</volume><fpage>143</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1038/nm.3443</pub-id><pub-id pub-id-type="pmid">24412922</pub-id><pub-id pub-id-type="pmcid">PMC3966466</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jegerlehner</surname><given-names>A</given-names></name><name name-style="western"><surname>Schmitz</surname><given-names>N</given-names></name><name name-style="western"><surname>Storni</surname><given-names>T</given-names></name><name name-style="western"><surname>Bachmann</surname><given-names>MF</given-names></name></person-group><article-title>Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity</article-title><source>J Immunol</source><year>2004</year><volume>172</volume><fpage>5598</fpage><lpage>5605</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.172.9.5598</pub-id><pub-id pub-id-type="pmid">15100303</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kohl</surname><given-names>S</given-names></name><name name-style="western"><surname>Loo</surname><given-names>LS</given-names></name><name name-style="western"><surname>Pickering</surname><given-names>LK</given-names></name></person-group><article-title>Protection of neonatal mice against herpes simplex viral infection by human antibody and leukocytes from adult, but not neonatal humans</article-title><source>J Immunol</source><year>1981</year><volume>127</volume><fpage>1273</fpage><lpage>1275</lpage><pub-id pub-id-type="pmid">7276559</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kohl</surname><given-names>S</given-names></name><name name-style="western"><surname>Loo</surname><given-names>LS</given-names></name></person-group><article-title>Protection of neonatal mice against herpes simplex virus infection: probable in vivo antibody-dependent cellular cytotoxicity</article-title><source>J Immunol</source><year>1982</year><volume>129</volume><fpage>370</fpage><lpage>376</lpage><pub-id pub-id-type="pmid">6282968</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Warfield</surname><given-names>KL</given-names></name><name name-style="western"><surname>Swenson</surname><given-names>DL</given-names></name><name name-style="western"><surname>Olinger</surname><given-names>GG</given-names></name><name name-style="western"><surname>Kalina</surname><given-names>WV</given-names></name><name name-style="western"><surname>Aman</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Bavari</surname><given-names>S</given-names></name></person-group><article-title>Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge</article-title><source>J Infect Dis</source><year>2007</year><volume>196</volume><issue>Suppl 2</issue><fpage>S430</fpage><lpage>S437</lpage><pub-id pub-id-type="doi">10.1086/520583</pub-id><pub-id pub-id-type="pmid">17940980</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bouharoun-Tayoun</surname><given-names>H</given-names></name><name name-style="western"><surname>Oeuvray</surname><given-names>C</given-names></name><name name-style="western"><surname>Lunel</surname><given-names>F</given-names></name><name name-style="western"><surname>Druilhe</surname><given-names>P</given-names></name></person-group><article-title>Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages</article-title><source>J Exp Med</source><year>1995</year><volume>182</volume><fpage>409</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1084/jem.182.2.409</pub-id><pub-id pub-id-type="pmid">7629503</pub-id><pub-id pub-id-type="pmcid">PMC2192140</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>J</given-names></name><name name-style="western"><surname>McIntosh</surname><given-names>RS</given-names></name><name name-style="western"><surname>Pleass</surname><given-names>RJ</given-names></name></person-group><article-title>Antibody- and Fc-receptor-based therapeutics for malaria</article-title><source>Clin Sci (Lond)</source><year>2006</year><volume>110</volume><fpage>11</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1042/CS20050136</pub-id><pub-id pub-id-type="pmid">16336201</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joos</surname><given-names>C</given-names></name><name name-style="western"><surname>Marrama</surname><given-names>L</given-names></name><name name-style="western"><surname>Polson</surname><given-names>HE</given-names></name><name name-style="western"><surname>Corre</surname><given-names>S</given-names></name><name name-style="western"><surname>Diatta</surname><given-names>AM</given-names></name><name name-style="western"><surname>Diouf</surname><given-names>B</given-names></name><name name-style="western"><surname>Trape</surname><given-names>JF</given-names></name><name name-style="western"><surname>Tall</surname><given-names>A</given-names></name><name name-style="western"><surname>Longacre</surname><given-names>S</given-names></name><name name-style="western"><surname>Perraut</surname><given-names>R</given-names></name></person-group><article-title>Clinical protection from falciparum malaria correlates with neutrophil respiratory bursts induced by merozoites opsonized with human serum antibodies</article-title><source>PLoS ONE</source><year>2010</year><volume>5</volume><fpage>e9871</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0009871</pub-id><pub-id pub-id-type="pmid">20360847</pub-id><pub-id pub-id-type="pmcid">PMC2845614</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCoy</surname><given-names>LE</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>RA</given-names></name></person-group><article-title>Neutralizing antibodies to HIV-1 induced by immunization</article-title><source>J Exp Med</source><year>2013</year><volume>210</volume><fpage>209</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1084/jem.20121827</pub-id><pub-id pub-id-type="pmid">23401570</pub-id><pub-id pub-id-type="pmcid">PMC3570100</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Excler</surname><given-names>JL</given-names></name><name name-style="western"><surname>Robb</surname><given-names>ML</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JH</given-names></name></person-group><article-title>Prospects for a globally effective HIV-1 vaccine</article-title><source>Am J Prev Med</source><year>2015</year><volume>49</volume><fpage>S307</fpage><lpage>S318</lpage><pub-id pub-id-type="doi">10.1016/j.amepre.2015.09.004</pub-id><pub-id pub-id-type="pmid">26590431</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rerks-Ngarm</surname><given-names>S</given-names></name><name name-style="western"><surname>Pitisuttithum</surname><given-names>P</given-names></name><name name-style="western"><surname>Nitayaphan</surname><given-names>S</given-names></name><name name-style="western"><surname>Kaewkungwal</surname><given-names>J</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>J</given-names></name><name name-style="western"><surname>Paris</surname><given-names>R</given-names></name><name name-style="western"><surname>Premsri</surname><given-names>N</given-names></name><name name-style="western"><surname>Namwat</surname><given-names>C</given-names></name><name name-style="western"><surname>de Souza</surname><given-names>M</given-names></name><name name-style="western"><surname>Adams</surname><given-names>E</given-names></name><etal/></person-group><article-title>Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand</article-title><source>N Engl J Med</source><year>2009</year><volume>361</volume><fpage>2209</fpage><lpage>2220</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0908492</pub-id><pub-id pub-id-type="pmid">19843557</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haynes</surname><given-names>BF</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>PB</given-names></name><name name-style="western"><surname>McElrath</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Zolla-Pazner</surname><given-names>S</given-names></name><name name-style="western"><surname>Tomaras</surname><given-names>GD</given-names></name><name name-style="western"><surname>Alam</surname><given-names>SM</given-names></name><name name-style="western"><surname>Evans</surname><given-names>DT</given-names></name><name name-style="western"><surname>Montefiori</surname><given-names>DC</given-names></name><name name-style="western"><surname>Karnasuta</surname><given-names>C</given-names></name><name name-style="western"><surname>Sutthent</surname><given-names>R</given-names></name><etal/></person-group><article-title>Immune-correlates analysis of an HIV-1 vaccine efficacy trial</article-title><source>New Engl J Med</source><year>2012</year><volume>366</volume><fpage>1275</fpage><lpage>1286</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1113425</pub-id><pub-id pub-id-type="pmid">22475592</pub-id><pub-id pub-id-type="pmcid">PMC3371689</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zolla-Pazner</surname><given-names>S</given-names></name><name name-style="western"><surname>deCamp</surname><given-names>A</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>PB</given-names></name><name name-style="western"><surname>Williams</surname><given-names>C</given-names></name><name name-style="western"><surname>Yates</surname><given-names>NL</given-names></name><name name-style="western"><surname>Williams</surname><given-names>WT</given-names></name><name name-style="western"><surname>Howington</surname><given-names>R</given-names></name><name name-style="western"><surname>Fong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Morris</surname><given-names>DE</given-names></name><name name-style="western"><surname>Soderberg</surname><given-names>KA</given-names></name><etal/></person-group><article-title>Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><fpage>e87572</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0087572</pub-id><pub-id pub-id-type="pmid">24504509</pub-id><pub-id pub-id-type="pmcid">PMC3913641</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>von Bubnoff</surname><given-names>A</given-names></name></person-group><article-title>Antibodies: beyond neutralization</article-title><source>IAVI Rep</source><year>2010</year><volume>14</volume><fpage>8</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">20349583</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ferrari</surname><given-names>G</given-names></name><name name-style="western"><surname>Alter</surname><given-names>G</given-names></name><name name-style="western"><surname>Forthal</surname><given-names>DN</given-names></name><name name-style="western"><surname>Kappes</surname><given-names>JC</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>GK</given-names></name><name name-style="western"><surname>Love</surname><given-names>JC</given-names></name><name name-style="western"><surname>Borate</surname><given-names>B</given-names></name><name name-style="western"><surname>Harris</surname><given-names>L</given-names></name><name name-style="western"><surname>Greene</surname><given-names>K</given-names></name><etal/></person-group><article-title>Diversity of antiviral IgG effector activities observed in HIV-infected and vaccinated subjects</article-title><source>J Immunol</source><year>2016</year><volume>197</volume><fpage>4603</fpage><lpage>4612</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1601197</pub-id><pub-id pub-id-type="pmid">27913647</pub-id><pub-id pub-id-type="pmcid">PMC5137799</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pitisuttithum</surname><given-names>P</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>P</given-names></name><name name-style="western"><surname>Gurwith</surname><given-names>M</given-names></name><name name-style="western"><surname>Heyward</surname><given-names>W</given-names></name><name name-style="western"><surname>Martin</surname><given-names>M</given-names></name><name name-style="western"><surname>van Griensven</surname><given-names>F</given-names></name><name name-style="western"><surname>Hu</surname><given-names>D</given-names></name><name name-style="western"><surname>Tappero</surname><given-names>JW</given-names></name><name name-style="western"><surname>Choopanya</surname><given-names>K</given-names></name></person-group><article-title>Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand</article-title><source>J Infect Dis</source><year>2006</year><volume>194</volume><fpage>1661</fpage><lpage>1671</lpage><pub-id pub-id-type="doi">10.1086/508748</pub-id><pub-id pub-id-type="pmid">17109337</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yates</surname><given-names>NL</given-names></name><name name-style="western"><surname>Liao</surname><given-names>HX</given-names></name><name name-style="western"><surname>Fong</surname><given-names>Y</given-names></name><name name-style="western"><surname>deCamp</surname><given-names>A</given-names></name><name name-style="western"><surname>Vandergrift</surname><given-names>NA</given-names></name><name name-style="western"><surname>Williams</surname><given-names>WT</given-names></name><name name-style="western"><surname>Alam</surname><given-names>SM</given-names></name><name name-style="western"><surname>Ferrari</surname><given-names>G</given-names></name><name name-style="western"><surname>Yang</surname><given-names>ZY</given-names></name><name name-style="western"><surname>Seaton</surname><given-names>KE</given-names></name><etal/></person-group><article-title>Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination</article-title><source>Sci Transl Med</source><year>2014</year><volume>6</volume><fpage>228ra239</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3007730</pub-id><pub-id pub-id-type="pmcid">PMC4116665</pub-id><pub-id pub-id-type="pmid">24648342</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>AW</given-names></name><name name-style="western"><surname>Ghebremichael</surname><given-names>M</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>H</given-names></name><name name-style="western"><surname>Brown</surname><given-names>E</given-names></name><name name-style="western"><surname>Choi</surname><given-names>I</given-names></name><name name-style="western"><surname>Lane</surname><given-names>S</given-names></name><name name-style="western"><surname>Dugast</surname><given-names>AS</given-names></name><name name-style="western"><surname>Schoen</surname><given-names>MK</given-names></name><name name-style="western"><surname>Rolland</surname><given-names>M</given-names></name><name name-style="western"><surname>Suscovich</surname><given-names>TJ</given-names></name><etal/></person-group><article-title>Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines</article-title><source>Sci Transl Med</source><year>2014</year><volume>6</volume><fpage>228ra238</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.3007736</pub-id><pub-id pub-id-type="pmid">24648341</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neuberger</surname><given-names>MS</given-names></name></person-group><article-title>Antibody diversification by somatic mutation: from Burnet onwards</article-title><source>Immunol Cell Biol</source><year>2008</year><volume>86</volume><fpage>124</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1038/sj.icb.7100160</pub-id><pub-id pub-id-type="pmid">18180793</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>AW</given-names></name><name name-style="western"><surname>Alter</surname><given-names>G</given-names></name></person-group><article-title>Dissecting the antibody constant region protective immune parameters in HIV infection</article-title><source>Future Virol</source><year>2014</year><volume>9</volume><fpage>397</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.2217/fvl.14.19</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koboldt</surname><given-names>DC</given-names></name><name name-style="western"><surname>Steinberg</surname><given-names>KM</given-names></name><name name-style="western"><surname>Larson</surname><given-names>DE</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>RK</given-names></name><name name-style="western"><surname>Mardis</surname><given-names>ER</given-names></name></person-group><article-title>The next-generation sequencing revolution and its impact on genomics</article-title><source>Cell</source><year>2013</year><volume>155</volume><fpage>27</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.09.006</pub-id><pub-id pub-id-type="pmid">24074859</pub-id><pub-id pub-id-type="pmcid">PMC3969849</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fellay</surname><given-names>J</given-names></name><name name-style="western"><surname>Shianna</surname><given-names>KV</given-names></name><name name-style="western"><surname>Telenti</surname><given-names>A</given-names></name><name name-style="western"><surname>Goldstein</surname><given-names>DB</given-names></name></person-group><article-title>Host genetics and HIV-1: the final phase?</article-title><source>PLoS Pathog</source><year>2010</year><volume>6</volume><fpage>e1001033</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1001033</pub-id><pub-id pub-id-type="pmid">20976252</pub-id><pub-id pub-id-type="pmcid">PMC2954832</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sorek</surname><given-names>R</given-names></name><name name-style="western"><surname>Cossart</surname><given-names>P</given-names></name></person-group><article-title>Prokaryotic transcriptomics: a new view on regulation, physiology and pathogenicity</article-title><source>Nat Rev Genet</source><year>2010</year><volume>11</volume><fpage>9</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1038/nrg2695</pub-id><pub-id pub-id-type="pmid">19935729</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pandey</surname><given-names>A</given-names></name><name name-style="western"><surname>Mann</surname><given-names>M</given-names></name></person-group><article-title>Proteomics to study genes and genomes</article-title><source>Nature</source><year>2000</year><volume>405</volume><fpage>837</fpage><lpage>846</lpage><pub-id pub-id-type="doi">10.1038/35015709</pub-id><pub-id pub-id-type="pmid">10866210</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spratlin</surname><given-names>JL</given-names></name><name name-style="western"><surname>Serkova</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Eckhardt</surname><given-names>SG</given-names></name></person-group><article-title>Clinical applications of metabolomics in oncology: a review</article-title><source>Clin Cancer Res</source><year>2009</year><volume>15</volume><fpage>431</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-1059</pub-id><pub-id pub-id-type="pmid">19147747</pub-id><pub-id pub-id-type="pmcid">PMC2676437</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>X</given-names></name><name name-style="western"><surname>Decker</surname><given-names>JM</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Hui</surname><given-names>H</given-names></name><name name-style="western"><surname>Kappes</surname><given-names>JC</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name><name name-style="western"><surname>Salazar-Gonzalez</surname><given-names>JF</given-names></name><name name-style="western"><surname>Salazar</surname><given-names>MG</given-names></name><name name-style="western"><surname>Kilby</surname><given-names>JM</given-names></name><name name-style="western"><surname>Saag</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Antibody neutralization and escape by HIV-1</article-title><source>Nature</source><year>2003</year><volume>422</volume><fpage>307</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1038/nature01470</pub-id><pub-id pub-id-type="pmid">12646921</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>AW</given-names></name><name name-style="western"><surname>Isitman</surname><given-names>G</given-names></name><name name-style="western"><surname>Navis</surname><given-names>M</given-names></name><name name-style="western"><surname>Kramski</surname><given-names>M</given-names></name><name name-style="western"><surname>Center</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Kent</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Stratov</surname><given-names>I</given-names></name></person-group><article-title>Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure</article-title><source>Proc Natl Acad Sci USA</source><year>2011</year><volume>108</volume><fpage>7505</fpage><lpage>7510</lpage><pub-id pub-id-type="doi">10.1073/pnas.1016048108</pub-id><pub-id pub-id-type="pmid">21502492</pub-id><pub-id pub-id-type="pmcid">PMC3088575</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sadanand</surname><given-names>S</given-names></name><name name-style="western"><surname>Suscovich</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Alter</surname><given-names>G</given-names></name></person-group><article-title>Broadly neutralizing antibodies against HIV: new insights to inform vaccine design</article-title><source>Annu Rev Med</source><year>2016</year><volume>67</volume><fpage>185</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1146/annurev-med-091014-090749</pub-id><pub-id pub-id-type="pmid">26565674</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonsignori</surname><given-names>M</given-names></name><name name-style="western"><surname>Pollara</surname><given-names>J</given-names></name><name name-style="western"><surname>Moody</surname><given-names>MA</given-names></name><name name-style="western"><surname>Alpert</surname><given-names>MD</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>KK</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>PB</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gurley</surname><given-names>TC</given-names></name><name name-style="western"><surname>Kozink</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family</article-title><source>J Virol</source><year>2012</year><volume>86</volume><fpage>11521</fpage><lpage>11532</lpage><pub-id pub-id-type="doi">10.1128/JVI.01023-12</pub-id><pub-id pub-id-type="pmid">22896626</pub-id><pub-id pub-id-type="pmcid">PMC3486290</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Madhavi</surname><given-names>V</given-names></name><name name-style="western"><surname>Wren</surname><given-names>LH</given-names></name><name name-style="western"><surname>Center</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Gonelli</surname><given-names>C</given-names></name><name name-style="western"><surname>Winnall</surname><given-names>WR</given-names></name><name name-style="western"><surname>Parsons</surname><given-names>MS</given-names></name><name name-style="western"><surname>Kramski</surname><given-names>M</given-names></name><name name-style="western"><surname>Kent</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Stratov</surname><given-names>I</given-names></name></person-group><article-title>Breadth of HIV-1 Env-specific antibody-dependent cellular cytotoxicity: relevance to global HIV vaccine design</article-title><source>AIDS</source><year>2014</year><volume>28</volume><fpage>1859</fpage><lpage>1870</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000000310</pub-id><pub-id pub-id-type="pmid">24937308</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McLean</surname><given-names>MR</given-names></name><name name-style="western"><surname>Madhavi</surname><given-names>V</given-names></name><name name-style="western"><surname>Wines</surname><given-names>BD</given-names></name><name name-style="western"><surname>Hogarth</surname><given-names>PM</given-names></name><name name-style="western"><surname>Chung</surname><given-names>AW</given-names></name><name name-style="western"><surname>Kent</surname><given-names>SJ</given-names></name></person-group><article-title>Dimeric Fcgamma Receptor Enzyme-Linked Immunosorbent Assay To Study HIV-Specific Antibodies: a New Look into Breadth of Fcgamma Receptor Antibodies Induced by the RV144 Vaccine Trial</article-title><source>J Immunol</source><year>2017</year><volume>199</volume><issue>2</issue><fpage>816</fpage><lpage>826</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1602161</pub-id><pub-id pub-id-type="pmid">28615419</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wren</surname><given-names>LH</given-names></name><name name-style="western"><surname>Chung</surname><given-names>AW</given-names></name><name name-style="western"><surname>Isitman</surname><given-names>G</given-names></name><name name-style="western"><surname>Kelleher</surname><given-names>AD</given-names></name><name name-style="western"><surname>Parsons</surname><given-names>MS</given-names></name><name name-style="western"><surname>Amin</surname><given-names>J</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>DA</given-names></name><name name-style="western"><surname>Stratov</surname><given-names>I</given-names></name><name name-style="western"><surname>Navis</surname><given-names>M</given-names></name><name name-style="western"><surname>Kent</surname><given-names>SJ</given-names></name></person-group><article-title>Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infection</article-title><source>Immunology</source><year>2013</year><volume>138</volume><fpage>116</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1111/imm.12016</pub-id><pub-id pub-id-type="pmid">23173935</pub-id><pub-id pub-id-type="pmcid">PMC3575764</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Isitman</surname><given-names>G</given-names></name><name name-style="western"><surname>Chung</surname><given-names>AW</given-names></name><name name-style="western"><surname>Navis</surname><given-names>M</given-names></name><name name-style="western"><surname>Kent</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Stratov</surname><given-names>I</given-names></name></person-group><article-title>Pol as a target for antibody dependent cellular cytotoxicity responses in HIV-1 infection</article-title><source>Virology</source><year>2011</year><volume>412</volume><fpage>110</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2010.12.044</pub-id><pub-id pub-id-type="pmid">21269655</pub-id><pub-id pub-id-type="pmcid">PMC3056898</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grunow</surname><given-names>R</given-names></name><name name-style="western"><surname>Franke</surname><given-names>L</given-names></name><name name-style="western"><surname>Hinkula</surname><given-names>J</given-names></name><name name-style="western"><surname>Wahren</surname><given-names>B</given-names></name><name name-style="western"><surname>Fenyo</surname><given-names>EM</given-names></name><name name-style="western"><surname>Jondal</surname><given-names>M</given-names></name><name name-style="western"><surname>von Baehr</surname><given-names>R</given-names></name></person-group><article-title>Monoclonal antibodies to p24-core protein of HIV-1 mediate ADCC and inhibit virus spread in vitro</article-title><source>Clin Diagn Virol</source><year>1995</year><volume>3</volume><fpage>221</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1016/S0928-0197(94)00039-5</pub-id><pub-id pub-id-type="pmid">15566804</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Madhavi</surname><given-names>V</given-names></name><name name-style="western"><surname>Wines</surname><given-names>BD</given-names></name><name name-style="western"><surname>Amin</surname><given-names>J</given-names></name><name name-style="western"><surname>Emery</surname><given-names>S</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>E</given-names></name><name name-style="western"><surname>Kelleher</surname><given-names>A</given-names></name><name name-style="western"><surname>Center</surname><given-names>R</given-names></name><name name-style="western"><surname>Hogarth</surname><given-names>PM</given-names></name><name name-style="western"><surname>Chung</surname><given-names>AW</given-names></name><name name-style="western"><surname>Kent</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Stratov</surname><given-names>I</given-names></name></person-group><article-title>HIV-1 Env- and Vpu-specific antibody-dependent cellular cytotoxicity responses associated with elite control of HIV</article-title><source>J Virol</source><year>2017</year><volume>91</volume><fpage>e00700-17</fpage><pub-id pub-id-type="doi">10.1128/JVI.00700-17</pub-id><pub-id pub-id-type="pmid">28701393</pub-id><pub-id pub-id-type="pmcid">PMC5571238</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lewis</surname><given-names>GK</given-names></name><name name-style="western"><surname>Finzi</surname><given-names>A</given-names></name><name name-style="western"><surname>DeVico</surname><given-names>AL</given-names></name><name name-style="western"><surname>Pazgier</surname><given-names>M</given-names></name></person-group><article-title>Conformational masking and receptor-dependent unmasking of highly conserved Env epitopes recognized by non-neutralizing antibodies that mediate potent ADCC against HIV-1</article-title><source>Viruses</source><year>2015</year><volume>7</volume><fpage>5115</fpage><lpage>5132</lpage><pub-id pub-id-type="doi">10.3390/v7092856</pub-id><pub-id pub-id-type="pmid">26393642</pub-id><pub-id pub-id-type="pmcid">PMC4584300</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hogarth</surname><given-names>PM</given-names></name><name name-style="western"><surname>Pietersz</surname><given-names>GA</given-names></name></person-group><article-title>Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond</article-title><source>Nat Rev Drug Discov</source><year>2012</year><volume>11</volume><fpage>311</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1038/nrd2909</pub-id><pub-id pub-id-type="pmid">22460124</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moraru</surname><given-names>M</given-names></name><name name-style="western"><surname>Black</surname><given-names>LE</given-names></name><name name-style="western"><surname>Muntasell</surname><given-names>A</given-names></name><name name-style="western"><surname>Portero</surname><given-names>F</given-names></name><name name-style="western"><surname>Lopez-Botet</surname><given-names>M</given-names></name><name name-style="western"><surname>Reyburn</surname><given-names>HT</given-names></name><name name-style="western"><surname>Pandey</surname><given-names>JP</given-names></name><name name-style="western"><surname>Vilches</surname><given-names>C</given-names></name></person-group><article-title>NK cell and Ig interplay in defense against herpes simplex virus type 1: epistatic interaction of CD16A and IgG1 allotypes of variable affinities modulates antibody-dependent cellular cytotoxicity and susceptibility to clinical reactivation</article-title><source>J Immunol</source><year>2015</year><volume>195</volume><fpage>1676</fpage><lpage>1684</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1500872</pub-id><pub-id pub-id-type="pmid">26179905</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shields</surname><given-names>RL</given-names></name><name name-style="western"><surname>Lai</surname><given-names>J</given-names></name><name name-style="western"><surname>Keck</surname><given-names>R</given-names></name><name name-style="western"><surname>O&#8217;Connell</surname><given-names>LY</given-names></name><name name-style="western"><surname>Hong</surname><given-names>K</given-names></name><name name-style="western"><surname>Meng</surname><given-names>YG</given-names></name><name name-style="western"><surname>Weikert</surname><given-names>SH</given-names></name><name name-style="western"><surname>Presta</surname><given-names>LG</given-names></name></person-group><article-title>Lack of fucose on human IgG1&#160;N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>26733</fpage><lpage>26740</lpage><pub-id pub-id-type="doi">10.1074/jbc.M202069200</pub-id><pub-id pub-id-type="pmid">11986321</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>AW</given-names></name><name name-style="western"><surname>Crispin</surname><given-names>M</given-names></name><name name-style="western"><surname>Pritchard</surname><given-names>L</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>H</given-names></name><name name-style="western"><surname>Gorny</surname><given-names>MK</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X</given-names></name><name name-style="western"><surname>Bailey-Kellogg</surname><given-names>C</given-names></name><name name-style="western"><surname>Ackerman</surname><given-names>ME</given-names></name><name name-style="western"><surname>Scanlan</surname><given-names>C</given-names></name><name name-style="western"><surname>Zolla-Pazner</surname><given-names>S</given-names></name><name name-style="western"><surname>Alter</surname><given-names>G</given-names></name></person-group><article-title>Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function</article-title><source>AIDS</source><year>2014</year><volume>28</volume><fpage>2523</fpage><lpage>2530</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000000444</pub-id><pub-id pub-id-type="pmid">25160934</pub-id><pub-id pub-id-type="pmcid">PMC4429604</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lux</surname><given-names>A</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X</given-names></name><name name-style="western"><surname>Scanlan</surname><given-names>CN</given-names></name><name name-style="western"><surname>Nimmerjahn</surname><given-names>F</given-names></name></person-group><article-title>Impact of immune complex size and glycosylation on IgG binding to human FcgammaRs</article-title><source>J Immunol</source><year>2013</year><volume>190</volume><fpage>4315</fpage><lpage>4323</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1200501</pub-id><pub-id pub-id-type="pmid">23509345</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ackerman</surname><given-names>ME</given-names></name><name name-style="western"><surname>Mikhailova</surname><given-names>A</given-names></name><name name-style="western"><surname>Brown</surname><given-names>EP</given-names></name><name name-style="western"><surname>Dowell</surname><given-names>KG</given-names></name><name name-style="western"><surname>Walker</surname><given-names>BD</given-names></name><name name-style="western"><surname>Bailey-Kellogg</surname><given-names>C</given-names></name><name name-style="western"><surname>Suscovich</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Alter</surname><given-names>G</given-names></name></person-group><article-title>Polyfunctional HIV-Specific antibody responses are associated with spontaneous HIV control</article-title><source>PLoS Pathog</source><year>2016</year><volume>12</volume><fpage>e1005315</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1005315</pub-id><pub-id pub-id-type="pmid">26745376</pub-id><pub-id pub-id-type="pmcid">PMC4706315</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banerjee</surname><given-names>K</given-names></name><name name-style="western"><surname>Klasse</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Sanders</surname><given-names>RW</given-names></name><name name-style="western"><surname>Pereyra</surname><given-names>F</given-names></name><name name-style="western"><surname>Michael</surname><given-names>E</given-names></name><name name-style="western"><surname>Lu</surname><given-names>M</given-names></name><name name-style="western"><surname>Walker</surname><given-names>BD</given-names></name><name name-style="western"><surname>Moore</surname><given-names>JP</given-names></name></person-group><article-title>IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines</article-title><source>AIDS Res Hum Retroviruses</source><year>2010</year><volume>26</volume><fpage>445</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1089/aid.2009.0223</pub-id><pub-id pub-id-type="pmid">20377426</pub-id><pub-id pub-id-type="pmcid">PMC2864049</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ackerman</surname><given-names>ME</given-names></name><name name-style="western"><surname>Crispin</surname><given-names>M</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X</given-names></name><name name-style="western"><surname>Baruah</surname><given-names>K</given-names></name><name name-style="western"><surname>Boesch</surname><given-names>AW</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Dugast</surname><given-names>AS</given-names></name><name name-style="western"><surname>Heizen</surname><given-names>EL</given-names></name><name name-style="western"><surname>Ercan</surname><given-names>A</given-names></name><name name-style="western"><surname>Choi</surname><given-names>I</given-names></name><etal/></person-group><article-title>Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity</article-title><source>J Clin Invest</source><year>2013</year><volume>123</volume><fpage>2183</fpage><lpage>2192</lpage><pub-id pub-id-type="doi">10.1172/JCI65708</pub-id><pub-id pub-id-type="pmid">23563315</pub-id><pub-id pub-id-type="pmcid">PMC3637034</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tomaras</surname><given-names>GD</given-names></name><name name-style="western"><surname>Ferrari</surname><given-names>G</given-names></name><name name-style="western"><surname>Shen</surname><given-names>X</given-names></name><name name-style="western"><surname>Alam</surname><given-names>SM</given-names></name><name name-style="western"><surname>Liao</surname><given-names>HX</given-names></name><name name-style="western"><surname>Pollara</surname><given-names>J</given-names></name><name name-style="western"><surname>Bonsignori</surname><given-names>M</given-names></name><name name-style="western"><surname>Moody</surname><given-names>MA</given-names></name><name name-style="western"><surname>Fong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><etal/></person-group><article-title>Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG</article-title><source>Proc Natl Acad Sci USA</source><year>2013</year><volume>110</volume><fpage>9019</fpage><lpage>9024</lpage><pub-id pub-id-type="doi">10.1073/pnas.1301456110</pub-id><pub-id pub-id-type="pmid">23661056</pub-id><pub-id pub-id-type="pmcid">PMC3670311</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watkins</surname><given-names>JD</given-names></name><name name-style="western"><surname>Sholukh</surname><given-names>AM</given-names></name><name name-style="western"><surname>Mukhtar</surname><given-names>MM</given-names></name><name name-style="western"><surname>Siddappa</surname><given-names>NB</given-names></name><name name-style="western"><surname>Lakhashe</surname><given-names>SK</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M</given-names></name><name name-style="western"><surname>Reinherz</surname><given-names>EL</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>S</given-names></name><name name-style="western"><surname>Forthal</surname><given-names>DN</given-names></name><name name-style="western"><surname>Sattentau</surname><given-names>QJ</given-names></name><etal/></person-group><article-title>Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission</article-title><source>AIDS</source><year>2013</year><volume>27</volume><fpage>F13</fpage><lpage>F20</lpage><pub-id pub-id-type="doi">10.1097/QAD.0b013e328360eac6</pub-id><pub-id pub-id-type="pmid">23775002</pub-id><pub-id pub-id-type="pmcid">PMC4084966</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baum</surname><given-names>LL</given-names></name><name name-style="western"><surname>Cassutt</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Knigge</surname><given-names>K</given-names></name><name name-style="western"><surname>Khattri</surname><given-names>R</given-names></name><name name-style="western"><surname>Margolick</surname><given-names>J</given-names></name><name name-style="western"><surname>Rinaldo</surname><given-names>C</given-names></name><name name-style="western"><surname>Kleeberger</surname><given-names>CA</given-names></name><name name-style="western"><surname>Nishanian</surname><given-names>P</given-names></name><name name-style="western"><surname>Henrard</surname><given-names>DR</given-names></name><name name-style="western"><surname>Phair</surname><given-names>J</given-names></name></person-group><article-title>HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression</article-title><source>J Immunol</source><year>1996</year><volume>157</volume><fpage>2168</fpage><lpage>2173</lpage><pub-id pub-id-type="pmid">8757343</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>A</given-names></name><name name-style="western"><surname>Rollman</surname><given-names>E</given-names></name><name name-style="western"><surname>Johansson</surname><given-names>S</given-names></name><name name-style="western"><surname>Kent</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Stratov</surname><given-names>I</given-names></name></person-group><article-title>The utility of ADCC responses in HIV infection</article-title><source>Curr HIV Res</source><year>2008</year><volume>6</volume><fpage>515</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.2174/157016208786501472</pub-id><pub-id pub-id-type="pmid">18991616</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ackerman</surname><given-names>ME</given-names></name><name name-style="western"><surname>Moldt</surname><given-names>B</given-names></name><name name-style="western"><surname>Wyatt</surname><given-names>RT</given-names></name><name name-style="western"><surname>Dugast</surname><given-names>AS</given-names></name><name name-style="western"><surname>McAndrew</surname><given-names>E</given-names></name><name name-style="western"><surname>Tsoukas</surname><given-names>S</given-names></name><name name-style="western"><surname>Jost</surname><given-names>S</given-names></name><name name-style="western"><surname>Berger</surname><given-names>CT</given-names></name><name name-style="western"><surname>Sciaranghella</surname><given-names>G</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name><etal/></person-group><article-title>A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples</article-title><source>J Immunol Methods</source><year>2011</year><volume>366</volume><fpage>8</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1016/j.jim.2010.12.016</pub-id><pub-id pub-id-type="pmid">21192942</pub-id><pub-id pub-id-type="pmcid">PMC3050993</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tay</surname><given-names>MZ</given-names></name><name name-style="western"><surname>Liu</surname><given-names>P</given-names></name><name name-style="western"><surname>Williams</surname><given-names>LD</given-names></name><name name-style="western"><surname>McRaven</surname><given-names>MD</given-names></name><name name-style="western"><surname>Sawant</surname><given-names>S</given-names></name><name name-style="western"><surname>Gurley</surname><given-names>TC</given-names></name><name name-style="western"><surname>Xu</surname><given-names>TT</given-names></name><name name-style="western"><surname>Dennison</surname><given-names>SM</given-names></name><name name-style="western"><surname>Liao</surname><given-names>HX</given-names></name><name name-style="western"><surname>Chenine</surname><given-names>AL</given-names></name><etal/></person-group><article-title>Antibody-mediated internalization of infectious HIV-1 virions differs among antibody isotypes and subclasses</article-title><source>PLoS Pathog</source><year>2016</year><volume>12</volume><fpage>e1005817</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1005817</pub-id><pub-id pub-id-type="pmid">27579713</pub-id><pub-id pub-id-type="pmcid">PMC5007037</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stratov</surname><given-names>I</given-names></name><name name-style="western"><surname>Chung</surname><given-names>A</given-names></name><name name-style="western"><surname>Kent</surname><given-names>SJ</given-names></name></person-group><article-title>Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIV-infected subjects</article-title><source>J Virol</source><year>2008</year><volume>82</volume><fpage>5450</fpage><lpage>5459</lpage><pub-id pub-id-type="doi">10.1128/JVI.01952-07</pub-id><pub-id pub-id-type="pmid">18353957</pub-id><pub-id pub-id-type="pmcid">PMC2395196</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gunn</surname><given-names>BM</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>JR</given-names></name><name name-style="western"><surname>Shansab</surname><given-names>M</given-names></name><name name-style="western"><surname>Bastian</surname><given-names>AR</given-names></name><name name-style="western"><surname>Fahrbach</surname><given-names>KM</given-names></name><name name-style="western"><surname>Smith</surname><given-names>AD</given-names></name><name name-style="western"><surname>Mahan</surname><given-names>AE</given-names></name><name name-style="western"><surname>Karim</surname><given-names>MM</given-names></name><name name-style="western"><surname>Licht</surname><given-names>AF</given-names></name><name name-style="western"><surname>Zvonar</surname><given-names>I</given-names></name><etal/></person-group><article-title>Enhanced binding of antibodies generated during chronic HIV infection to mucus component MUC16</article-title><source>Mucosal Immunol</source><year>2016</year><volume>9</volume><fpage>1549</fpage><lpage>1558</lpage><pub-id pub-id-type="doi">10.1038/mi.2016.8</pub-id><pub-id pub-id-type="pmid">26960182</pub-id><pub-id pub-id-type="pmcid">PMC5017893</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmad</surname><given-names>A</given-names></name><name name-style="western"><surname>Menezes</surname><given-names>J</given-names></name></person-group><article-title>Antibody-dependent cellular cytotoxicity in HIV infections</article-title><source>Faseb J</source><year>1996</year><volume>10</volume><fpage>258</fpage><lpage>266</lpage><pub-id pub-id-type="pmid">8641559</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fasebj.10.2.8641559</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tamura</surname><given-names>K</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>C</given-names></name><name name-style="western"><surname>Hojo</surname><given-names>T</given-names></name><name name-style="western"><surname>Akashi-Tanaka</surname><given-names>S</given-names></name><name name-style="western"><surname>Kinoshita</surname><given-names>T</given-names></name><name name-style="western"><surname>Yonemori</surname><given-names>K</given-names></name><name name-style="western"><surname>Kouno</surname><given-names>T</given-names></name><name name-style="western"><surname>Katsumata</surname><given-names>N</given-names></name><name name-style="western"><surname>Ando</surname><given-names>M</given-names></name><name name-style="western"><surname>Aogi</surname><given-names>K</given-names></name><etal/></person-group><article-title>FcgammaR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer</article-title><source>Ann Oncol</source><year>2011</year><volume>22</volume><fpage>1302</fpage><lpage>1307</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdq585</pub-id><pub-id pub-id-type="pmid">21109570</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forthal</surname><given-names>DN</given-names></name><name name-style="western"><surname>Landucci</surname><given-names>G</given-names></name><name name-style="western"><surname>Bream</surname><given-names>J</given-names></name><name name-style="western"><surname>Jacobson</surname><given-names>LP</given-names></name><name name-style="western"><surname>Phan</surname><given-names>TB</given-names></name><name name-style="western"><surname>Montoya</surname><given-names>B</given-names></name></person-group><article-title>FcgammaRIIa genotype predicts progression of HIV infection</article-title><source>J Immunol</source><year>2007</year><volume>179</volume><fpage>7916</fpage><lpage>7923</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.179.11.7916</pub-id><pub-id pub-id-type="pmid">18025239</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanders</surname><given-names>LA</given-names></name><name name-style="western"><surname>Feldman</surname><given-names>RG</given-names></name><name name-style="western"><surname>Voorhorst-Ogink</surname><given-names>MM</given-names></name><name name-style="western"><surname>de Haas</surname><given-names>M</given-names></name><name name-style="western"><surname>Rijkers</surname><given-names>GT</given-names></name><name name-style="western"><surname>Capel</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Zegers</surname><given-names>BJ</given-names></name><name name-style="western"><surname>van de Winkel</surname><given-names>JG</given-names></name></person-group><article-title>Human immunoglobulin G (IgG) Fc receptor IIA (CD32) polymorphism and IgG2-mediated bacterial phagocytosis by neutrophils</article-title><source>Infect Immun</source><year>1995</year><volume>63</volume><fpage>73</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">7806386</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.63.1.73-81.1995</pub-id><pub-id pub-id-type="pmcid">PMC172959</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Erbe</surname><given-names>AK</given-names></name><name name-style="western"><surname>Hank</surname><given-names>JA</given-names></name><name name-style="western"><surname>Morris</surname><given-names>ZS</given-names></name><name name-style="western"><surname>Sondel</surname><given-names>PM</given-names></name></person-group><article-title>NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy</article-title><source>Front Immunol</source><year>2015</year><volume>6</volume><fpage>368</fpage><pub-id pub-id-type="pmid">26284063</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2015.00368</pub-id><pub-id pub-id-type="pmcid">PMC4515552</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cartron</surname><given-names>G</given-names></name><name name-style="western"><surname>Dacheux</surname><given-names>L</given-names></name><name name-style="western"><surname>Salles</surname><given-names>G</given-names></name><name name-style="western"><surname>Solal-Celigny</surname><given-names>P</given-names></name><name name-style="western"><surname>Bardos</surname><given-names>P</given-names></name><name name-style="western"><surname>Colombat</surname><given-names>P</given-names></name><name name-style="western"><surname>Watier</surname><given-names>H</given-names></name></person-group><article-title>Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene</article-title><source>Blood</source><year>2002</year><volume>99</volume><fpage>754</fpage><lpage>758</lpage><pub-id pub-id-type="doi">10.1182/blood.V99.3.754</pub-id><pub-id pub-id-type="pmid">11806974</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poonia</surname><given-names>B</given-names></name><name name-style="western"><surname>Kijak</surname><given-names>GH</given-names></name><name name-style="western"><surname>Pauza</surname><given-names>CD</given-names></name></person-group><article-title>High affinity allele for the gene of FCGR3A is risk factor for HIV infection and progression</article-title><source>PLoS ONE</source><year>2010</year><volume>5</volume><fpage>e15562</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0015562</pub-id><pub-id pub-id-type="pmid">21187939</pub-id><pub-id pub-id-type="pmcid">PMC3004964</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forthal</surname><given-names>DN</given-names></name><name name-style="western"><surname>Gabriel</surname><given-names>EE</given-names></name><name name-style="western"><surname>Wang</surname><given-names>A</given-names></name><name name-style="western"><surname>Landucci</surname><given-names>G</given-names></name><name name-style="western"><surname>Phan</surname><given-names>TB</given-names></name></person-group><article-title>Association of Fcgamma receptor IIIa genotype with the rate of HIV infection after gp120 vaccination</article-title><source>Blood</source><year>2012</year><volume>120</volume><fpage>2836</fpage><lpage>2842</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-05-431361</pub-id><pub-id pub-id-type="pmid">22915639</pub-id><pub-id pub-id-type="pmcid">PMC3466964</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheeseman</surname><given-names>HM</given-names></name><name name-style="western"><surname>Carias</surname><given-names>AM</given-names></name><name name-style="western"><surname>Evans</surname><given-names>AB</given-names></name><name name-style="western"><surname>Olejniczak</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Ziprin</surname><given-names>P</given-names></name><name name-style="western"><surname>King</surname><given-names>DF</given-names></name><name name-style="western"><surname>Hope</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Shattock</surname><given-names>RJ</given-names></name></person-group><article-title>Expression profile of human fc receptors in mucosal tissue: implications for antibody-dependent cellular effector functions targeting HIV-1 transmission</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><fpage>e0154656</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0154656</pub-id><pub-id pub-id-type="pmid">27164006</pub-id><pub-id pub-id-type="pmcid">PMC4862624</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Birmingham</surname><given-names>A</given-names></name><name name-style="western"><surname>Selfors</surname><given-names>LM</given-names></name><name name-style="western"><surname>Forster</surname><given-names>T</given-names></name><name name-style="western"><surname>Wrobel</surname><given-names>D</given-names></name><name name-style="western"><surname>Kennedy</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Shanks</surname><given-names>E</given-names></name><name name-style="western"><surname>Santoyo-Lopez</surname><given-names>J</given-names></name><name name-style="western"><surname>Dunican</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Long</surname><given-names>A</given-names></name><name name-style="western"><surname>Kelleher</surname><given-names>D</given-names></name><etal/></person-group><article-title>Statistical methods for analysis of high-throughput RNA interference screens</article-title><source>Nat Methods</source><year>2009</year><volume>6</volume><fpage>569</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1351</pub-id><pub-id pub-id-type="pmid">19644458</pub-id><pub-id pub-id-type="pmcid">PMC2789971</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alpert</surname><given-names>MD</given-names></name><name name-style="western"><surname>Heyer</surname><given-names>LN</given-names></name><name name-style="western"><surname>Williams</surname><given-names>DE</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>JD</given-names></name><name name-style="western"><surname>Greenough</surname><given-names>T</given-names></name><name name-style="western"><surname>Allhorn</surname><given-names>M</given-names></name><name name-style="western"><surname>Evans</surname><given-names>DT</given-names></name></person-group><article-title>A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays</article-title><source>J Virol</source><year>2012</year><volume>86</volume><fpage>12039</fpage><lpage>12052</lpage><pub-id pub-id-type="doi">10.1128/JVI.01650-12</pub-id><pub-id pub-id-type="pmid">22933282</pub-id><pub-id pub-id-type="pmcid">PMC3486484</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qin</surname><given-names>Z</given-names></name></person-group><article-title>The use of THP-1 cells as a model for mimicking the function and regulation of monocytes and macrophages in the vasculature</article-title><source>Atherosclerosis</source><year>2012</year><volume>221</volume><fpage>2</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2011.09.003</pub-id><pub-id pub-id-type="pmid">21978918</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raudys</surname><given-names>S</given-names></name><name name-style="western"><surname>Jain</surname><given-names>A</given-names></name></person-group><article-title>Small sample size effects in statistical pattern recognition: recommendations for practitioners</article-title><source>IEEE Trans Pattern Anal Mach Intell</source><year>1991</year><volume>13</volume><fpage>252</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1109/34.75512</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tarca</surname><given-names>AL</given-names></name><name name-style="western"><surname>Carey</surname><given-names>VJ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>XW</given-names></name><name name-style="western"><surname>Romero</surname><given-names>R</given-names></name><name name-style="western"><surname>Draghici</surname><given-names>S</given-names></name></person-group><article-title>Machine learning and its applications to biology</article-title><source>PLoS Comput Biol</source><year>2007</year><volume>3</volume><fpage>e116</fpage><pub-id pub-id-type="doi">10.1371/journal.pcbi.0030116</pub-id><pub-id pub-id-type="pmid">17604446</pub-id><pub-id pub-id-type="pmcid">PMC1904382</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakaya</surname><given-names>HI</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Pulendran</surname><given-names>B</given-names></name></person-group><article-title>Systems vaccinology: learning to compute the behavior of vaccine induced immunity</article-title><source>Wiley Interdiscip Rev Syst Biol Med</source><year>2012</year><volume>4</volume><fpage>193</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1002/wsbm.163</pub-id><pub-id pub-id-type="pmid">22012654</pub-id><pub-id pub-id-type="pmcid">PMC3288517</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arnold</surname><given-names>KB</given-names></name><name name-style="western"><surname>Chung</surname><given-names>AW</given-names></name></person-group><source>Prospects from systems serology research. Immunology.</source><year>2017</year><pub-id pub-id-type="pmid">29139548</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/imm.12861</pub-id><pub-id pub-id-type="pmcid">PMC5795183</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>I</given-names></name><name name-style="western"><surname>Chung</surname><given-names>AW</given-names></name><name name-style="western"><surname>Suscovich</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Rerks-Ngarm</surname><given-names>S</given-names></name><name name-style="western"><surname>Pitisuttithum</surname><given-names>P</given-names></name><name name-style="western"><surname>Nitayaphan</surname><given-names>S</given-names></name><name name-style="western"><surname>Kaewkungwal</surname><given-names>J</given-names></name><name name-style="western"><surname>O&#8217;Connell</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Francis</surname><given-names>D</given-names></name><name name-style="western"><surname>Robb</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Machine learning methods enable predictive modeling of antibody feature:function relationships in RV144 vaccinees</article-title><source>PLoS Comput Biol</source><year>2015</year><volume>11</volume><fpage>e1004185</fpage><pub-id pub-id-type="doi">10.1371/journal.pcbi.1004185</pub-id><pub-id pub-id-type="pmid">25874406</pub-id><pub-id pub-id-type="pmcid">PMC4395155</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>LL</given-names></name><name name-style="western"><surname>Chung</surname><given-names>AW</given-names></name><name name-style="western"><surname>Rosebrock</surname><given-names>TR</given-names></name><name name-style="western"><surname>Ghebremichael</surname><given-names>M</given-names></name><name name-style="western"><surname>Yu</surname><given-names>WH</given-names></name><name name-style="western"><surname>Grace</surname><given-names>PS</given-names></name><name name-style="western"><surname>Schoen</surname><given-names>MK</given-names></name><name name-style="western"><surname>Tafesse</surname><given-names>F</given-names></name><name name-style="western"><surname>Martin</surname><given-names>C</given-names></name><name name-style="western"><surname>Leung</surname><given-names>V</given-names></name><etal/></person-group><article-title>A functional role for antibodies in tuberculosis</article-title><source>Cell</source><year>2016</year><volume>167</volume><issue>433&#8211;443</issue><fpage>e414</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2016.08.072</pub-id><pub-id pub-id-type="pmcid">PMC5526202</pub-id><pub-id pub-id-type="pmid">27667685</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>AW</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>MP</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>KB</given-names></name><name name-style="western"><surname>Yu</surname><given-names>WH</given-names></name><name name-style="western"><surname>Schoen</surname><given-names>MK</given-names></name><name name-style="western"><surname>Dunphy</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Suscovich</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Frahm</surname><given-names>N</given-names></name><name name-style="western"><surname>Linde</surname><given-names>C</given-names></name><name name-style="western"><surname>Mahan</surname><given-names>AE</given-names></name><etal/></person-group><article-title>Dissecting polyclonal vaccine-induced humoral immunity against HIV using systems serology</article-title><source>Cell</source><year>2015</year><volume>163</volume><fpage>988</fpage><lpage>998</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.10.027</pub-id><pub-id pub-id-type="pmid">26544943</pub-id><pub-id pub-id-type="pmcid">PMC5490491</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Archary</surname><given-names>D</given-names></name><name name-style="western"><surname>Seaton</surname><given-names>KE</given-names></name><name name-style="western"><surname>Passmore</surname><given-names>JS</given-names></name><name name-style="western"><surname>Werner</surname><given-names>L</given-names></name><name name-style="western"><surname>Deal</surname><given-names>A</given-names></name><name name-style="western"><surname>Dunphy</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>KB</given-names></name><name name-style="western"><surname>Yates</surname><given-names>NL</given-names></name><name name-style="western"><surname>Lauffenburger</surname><given-names>DA</given-names></name><name name-style="western"><surname>Bergin</surname><given-names>P</given-names></name><etal/></person-group><article-title>Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel</article-title><source>Mucosal Immunol</source><year>2016</year><volume>9</volume><fpage>821</fpage><lpage>833</lpage><pub-id pub-id-type="doi">10.1038/mi.2015.145</pub-id><pub-id pub-id-type="pmid">26813340</pub-id><pub-id pub-id-type="pmcid">PMC4848129</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barouch</surname><given-names>DH</given-names></name><name name-style="western"><surname>Alter</surname><given-names>G</given-names></name><name name-style="western"><surname>Broge</surname><given-names>T</given-names></name><name name-style="western"><surname>Linde</surname><given-names>C</given-names></name><name name-style="western"><surname>Ackerman</surname><given-names>ME</given-names></name><name name-style="western"><surname>Brown</surname><given-names>EP</given-names></name><name name-style="western"><surname>Borducchi</surname><given-names>EN</given-names></name><name name-style="western"><surname>Smith</surname><given-names>KM</given-names></name><name name-style="western"><surname>Nkolola</surname><given-names>JP</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Protective efficacy of adenovirus-protein vaccines against SIV challenges in rhesus monkeys</article-title><source>Science</source><year>2015</year><volume>349</volume><fpage>320</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1126/science.aab3886</pub-id><pub-id pub-id-type="pmid">26138104</pub-id><pub-id pub-id-type="pmcid">PMC4653134</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>EP</given-names></name><name name-style="western"><surname>Dowell</surname><given-names>KG</given-names></name><name name-style="western"><surname>Boesch</surname><given-names>AW</given-names></name><name name-style="western"><surname>Normandin</surname><given-names>E</given-names></name><name name-style="western"><surname>Mahan</surname><given-names>AE</given-names></name><name name-style="western"><surname>Chu</surname><given-names>T</given-names></name><name name-style="western"><surname>Barouch</surname><given-names>DH</given-names></name><name name-style="western"><surname>Bailey-Kellogg</surname><given-names>C</given-names></name><name name-style="western"><surname>Alter</surname><given-names>G</given-names></name><name name-style="western"><surname>Ackerman</surname><given-names>ME</given-names></name></person-group><article-title>Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles</article-title><source>J Immunol Methods</source><year>2017</year><volume>443</volume><fpage>33</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.jim.2017.01.010</pub-id><pub-id pub-id-type="pmid">28163018</pub-id><pub-id pub-id-type="pmcid">PMC5333794</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnstone</surname><given-names>IM</given-names></name><name name-style="western"><surname>Titterington</surname><given-names>DM</given-names></name></person-group><article-title>Statistical challenges of high-dimensional data</article-title><source>Philos Trans A Math Phys Eng Sci</source><year>2009</year><volume>367</volume><fpage>4237</fpage><lpage>4253</lpage><pub-id pub-id-type="doi">10.1098/rsta.2009.0159</pub-id><pub-id pub-id-type="pmid">19805443</pub-id><pub-id pub-id-type="pmcid">PMC2865881</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saeys</surname><given-names>Y</given-names></name><name name-style="western"><surname>Inza</surname><given-names>I</given-names></name><name name-style="western"><surname>Larranaga</surname><given-names>P</given-names></name></person-group><article-title>A review of feature selection techniques in bioinformatics</article-title><source>Bioinformatics</source><year>2007</year><volume>23</volume><fpage>2507</fpage><lpage>2517</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btm344</pub-id><pub-id pub-id-type="pmid">17720704</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Querec</surname><given-names>TD</given-names></name><name name-style="western"><surname>Akondy</surname><given-names>RS</given-names></name><name name-style="western"><surname>Lee</surname><given-names>EK</given-names></name><name name-style="western"><surname>Cao</surname><given-names>W</given-names></name><name name-style="western"><surname>Nakaya</surname><given-names>HI</given-names></name><name name-style="western"><surname>Teuwen</surname><given-names>D</given-names></name><name name-style="western"><surname>Pirani</surname><given-names>A</given-names></name><name name-style="western"><surname>Gernert</surname><given-names>K</given-names></name><name name-style="western"><surname>Deng</surname><given-names>J</given-names></name><name name-style="western"><surname>Marzolf</surname><given-names>B</given-names></name><etal/></person-group><article-title>Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans</article-title><source>Nat Immunol</source><year>2009</year><volume>10</volume><fpage>116</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1038/ni.1688</pub-id><pub-id pub-id-type="pmid">19029902</pub-id><pub-id pub-id-type="pmcid">PMC4049462</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakaya</surname><given-names>HI</given-names></name><name name-style="western"><surname>Wrammert</surname><given-names>J</given-names></name><name name-style="western"><surname>Lee</surname><given-names>EK</given-names></name><name name-style="western"><surname>Racioppi</surname><given-names>L</given-names></name><name name-style="western"><surname>Marie-Kunze</surname><given-names>S</given-names></name><name name-style="western"><surname>Haining</surname><given-names>WN</given-names></name><name name-style="western"><surname>Means</surname><given-names>AR</given-names></name><name name-style="western"><surname>Kasturi</surname><given-names>SP</given-names></name><name name-style="western"><surname>Khan</surname><given-names>N</given-names></name><name name-style="western"><surname>Li</surname><given-names>GM</given-names></name><etal/></person-group><article-title>Systems biology of vaccination for seasonal influenza in humans</article-title><source>Nat Immunol</source><year>2011</year><volume>12</volume><fpage>786</fpage><lpage>795</lpage><pub-id pub-id-type="doi">10.1038/ni.2067</pub-id><pub-id pub-id-type="pmid">21743478</pub-id><pub-id pub-id-type="pmcid">PMC3140559</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vahey</surname><given-names>MT</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Kester</surname><given-names>KE</given-names></name><name name-style="western"><surname>Cummings</surname><given-names>J</given-names></name><name name-style="western"><surname>Heppner</surname><given-names>DG</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Nau</surname><given-names>ME</given-names></name><name name-style="western"><surname>Ofori-Anyinam</surname><given-names>O</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>J</given-names></name><name name-style="western"><surname>Coche</surname><given-names>T</given-names></name><name name-style="western"><surname>Ballou</surname><given-names>WR</given-names></name><name name-style="western"><surname>Ockenhouse</surname><given-names>CF</given-names></name></person-group><article-title>Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS, S malaria vaccine</article-title><source>J Infect Dis</source><year>2010</year><volume>201</volume><fpage>580</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1086/650310</pub-id><pub-id pub-id-type="pmid">20078211</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kazmin</surname><given-names>D</given-names></name><name name-style="western"><surname>Nakaya</surname><given-names>HI</given-names></name><name name-style="western"><surname>Lee</surname><given-names>EK</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>MJ</given-names></name><name name-style="western"><surname>van der Most</surname><given-names>R</given-names></name><name name-style="western"><surname>van den Berg</surname><given-names>RA</given-names></name><name name-style="western"><surname>Ballou</surname><given-names>WR</given-names></name><name name-style="western"><surname>Jongert</surname><given-names>E</given-names></name><name name-style="western"><surname>Wille-Reece</surname><given-names>U</given-names></name><name name-style="western"><surname>Ockenhouse</surname><given-names>C</given-names></name><etal/></person-group><article-title>Systems analysis of protective immune responses to RTS, S malaria vaccination in humans</article-title><source>Proc Natl Acad Sci U S A</source><year>2017</year><volume>114</volume><fpage>2425</fpage><lpage>2430</lpage><pub-id pub-id-type="doi">10.1073/pnas.1621489114</pub-id><pub-id pub-id-type="pmid">28193898</pub-id><pub-id pub-id-type="pmcid">PMC5338562</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Churchyard</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>C</given-names></name><name name-style="western"><surname>Adams</surname><given-names>E</given-names></name><name name-style="western"><surname>Hural</surname><given-names>J</given-names></name><name name-style="western"><surname>Graham</surname><given-names>BS</given-names></name><name name-style="western"><surname>Moodie</surname><given-names>Z</given-names></name><name name-style="western"><surname>Grove</surname><given-names>D</given-names></name><name name-style="western"><surname>Gray</surname><given-names>G</given-names></name><name name-style="western"><surname>Bekker</surname><given-names>LG</given-names></name><name name-style="western"><surname>McElrath</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204)</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><fpage>e21225</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0021225</pub-id><pub-id pub-id-type="pmid">21857901</pub-id><pub-id pub-id-type="pmcid">PMC3152265</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tibshirani</surname><given-names>R</given-names></name></person-group><article-title>The lasso method for variable selection in the Cox model</article-title><source>Stat Med</source><year>1997</year><volume>16</volume><fpage>385</fpage><lpage>395</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(SICI)1097-0258(19970228)16:4&amp;#x0003c;385::AID-SIM380&amp;#x0003e;3.0.CO;2-3</pub-id><pub-id pub-id-type="pmid">9044528</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arnold</surname><given-names>KB</given-names></name><name name-style="western"><surname>Burgener</surname><given-names>A</given-names></name><name name-style="western"><surname>Birse</surname><given-names>K</given-names></name><name name-style="western"><surname>Romas</surname><given-names>L</given-names></name><name name-style="western"><surname>Dunphy</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Shahabi</surname><given-names>K</given-names></name><name name-style="western"><surname>Abou</surname><given-names>M</given-names></name><name name-style="western"><surname>Westmacott</surname><given-names>GR</given-names></name><name name-style="western"><surname>McCorrister</surname><given-names>S</given-names></name><name name-style="western"><surname>Kwatampora</surname><given-names>J</given-names></name><etal/></person-group><article-title>Increased levels of inflammatory cytokines in the female reproductive tract are associated with altered expression of proteases, mucosal barrier proteins, and an influx of HIV-susceptible target cells</article-title><source>Mucosal Immunol</source><year>2015</year><volume>9</volume><fpage>194</fpage><pub-id pub-id-type="doi">10.1038/mi.2015.51</pub-id><pub-id pub-id-type="pmid">26104913</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barabasi</surname><given-names>AL</given-names></name><name name-style="western"><surname>Oltvai</surname><given-names>ZN</given-names></name></person-group><article-title>Network biology: understanding the cell&#8217;s functional organization</article-title><source>Nat Rev Genet</source><year>2004</year><volume>5</volume><fpage>101</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1038/nrg1272</pub-id><pub-id pub-id-type="pmid">14735121</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yook</surname><given-names>SH</given-names></name><name name-style="western"><surname>Oltvai</surname><given-names>ZN</given-names></name><name name-style="western"><surname>Barabasi</surname><given-names>AL</given-names></name></person-group><article-title>Functional and topological characterization of protein interaction networks</article-title><source>Proteomics</source><year>2004</year><volume>4</volume><fpage>928</fpage><lpage>942</lpage><pub-id pub-id-type="doi">10.1002/pmic.200300636</pub-id><pub-id pub-id-type="pmid">15048975</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bradley</surname><given-names>T</given-names></name><name name-style="western"><surname>Pollara</surname><given-names>J</given-names></name><name name-style="western"><surname>Santra</surname><given-names>S</given-names></name><name name-style="western"><surname>Vandergrift</surname><given-names>N</given-names></name><name name-style="western"><surname>Pittala</surname><given-names>S</given-names></name><name name-style="western"><surname>Bailey-Kellogg</surname><given-names>C</given-names></name><name name-style="western"><surname>Shen</surname><given-names>X</given-names></name><name name-style="western"><surname>Parks</surname><given-names>R</given-names></name><name name-style="western"><surname>Goodman</surname><given-names>D</given-names></name><name name-style="western"><surname>Eaton</surname><given-names>A</given-names></name><etal/></person-group><article-title>Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge</article-title><source>Nat Commun</source><year>2017</year><volume>8</volume><fpage>15711</fpage><pub-id pub-id-type="doi">10.1038/ncomms15711</pub-id><pub-id pub-id-type="pmid">28593989</pub-id><pub-id pub-id-type="pmcid">PMC5472724</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vaccari</surname><given-names>M</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>SN</given-names></name><name name-style="western"><surname>Fourati</surname><given-names>S</given-names></name><name name-style="western"><surname>Schifanella</surname><given-names>L</given-names></name><name name-style="western"><surname>Liyanage</surname><given-names>NPM</given-names></name><name name-style="western"><surname>Cameron</surname><given-names>M</given-names></name><name name-style="western"><surname>Keele</surname><given-names>BF</given-names></name><name name-style="western"><surname>Shen</surname><given-names>XY</given-names></name><name name-style="western"><surname>Tomaras</surname><given-names>GD</given-names></name><name name-style="western"><surname>Billings</surname><given-names>E</given-names></name><etal/></person-group><article-title>Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition</article-title><source>Nat Med</source><year>2016</year><volume>22</volume><fpage>762</fpage><lpage>770</lpage><pub-id pub-id-type="doi">10.1038/nm.4105</pub-id><pub-id pub-id-type="pmid">27239761</pub-id><pub-id pub-id-type="pmcid">PMC5916782</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>SL</given-names></name></person-group><article-title>Non-human primate models for AIDS vaccine research</article-title><source>Curr Drug Targets Infect Disord</source><year>2005</year><volume>5</volume><fpage>193</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.2174/1568005054201508</pub-id><pub-id pub-id-type="pmid">15975024</pub-id><pub-id pub-id-type="pmcid">PMC1488817</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>YN</given-names></name><name name-style="western"><surname>Boesch</surname><given-names>AW</given-names></name><name name-style="western"><surname>Osei-Owusu</surname><given-names>NY</given-names></name><name name-style="western"><surname>Emileh</surname><given-names>A</given-names></name><name name-style="western"><surname>Crowley</surname><given-names>AR</given-names></name><name name-style="western"><surname>Cocklin</surname><given-names>SL</given-names></name><name name-style="western"><surname>Finstad</surname><given-names>SL</given-names></name><name name-style="western"><surname>Linde</surname><given-names>CH</given-names></name><name name-style="western"><surname>Howell</surname><given-names>RA</given-names></name><name name-style="western"><surname>Zentner</surname><given-names>I</given-names></name><etal/></person-group><article-title>IgG binding characteristics of rhesus macaque FcgammaR</article-title><source>J Immunol</source><year>2016</year><volume>197</volume><fpage>2936</fpage><lpage>2947</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1502252</pub-id><pub-id pub-id-type="pmid">27559046</pub-id><pub-id pub-id-type="pmcid">PMC5026948</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>HX</given-names></name><name name-style="western"><surname>Lynch</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>T</given-names></name><name name-style="western"><surname>Gao</surname><given-names>F</given-names></name><name name-style="western"><surname>Alam</surname><given-names>SM</given-names></name><name name-style="western"><surname>Boyd</surname><given-names>SD</given-names></name><name name-style="western"><surname>Fire</surname><given-names>AZ</given-names></name><name name-style="western"><surname>Roskin</surname><given-names>KM</given-names></name><name name-style="western"><surname>Schramm</surname><given-names>CA</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus</article-title><source>Nature</source><year>2013</year><volume>496</volume><fpage>469</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1038/nature12053</pub-id><pub-id pub-id-type="pmid">23552890</pub-id><pub-id pub-id-type="pmcid">PMC3637846</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>EP</given-names></name><name name-style="western"><surname>Licht</surname><given-names>AF</given-names></name><name name-style="western"><surname>Dugast</surname><given-names>AS</given-names></name><name name-style="western"><surname>Choi</surname><given-names>I</given-names></name><name name-style="western"><surname>Bailey-Kellogg</surname><given-names>C</given-names></name><name name-style="western"><surname>Alter</surname><given-names>G</given-names></name><name name-style="western"><surname>Ackerman</surname><given-names>ME</given-names></name></person-group><article-title>High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples</article-title><source>J Immunol Methods</source><year>2012</year><volume>386</volume><fpage>117</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1016/j.jim.2012.09.007</pub-id><pub-id pub-id-type="pmid">23023091</pub-id><pub-id pub-id-type="pmcid">PMC3475184</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klasse</surname><given-names>PJ</given-names></name></person-group><article-title>How to assess the binding strength of antibodies elicited by vaccination against HIV and other viruses</article-title><source>Expert Rev Vaccines</source><year>2016</year><volume>15</volume><fpage>295</fpage><lpage>311</lpage><pub-id pub-id-type="pmid">26641943</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/14760584.2016.1128831</pub-id><pub-id pub-id-type="pmcid">PMC4766047</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><mixed-citation publication-type="other">Mahan A, Tedesco J, Dionne K, Chung A, Cox J, Koff W, Barouch D, Michael N, Kim J, Suscovich T, Alter G: Antibody Glycosylation Can Be Transiently Altered After Vaccination Against HIV. AIDS Vaccine Barc 2013, P03.18.</mixed-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Raso</surname><given-names>SW</given-names></name><name name-style="western"><surname>Entrican</surname><given-names>C</given-names></name><name name-style="western"><surname>Tangarone</surname><given-names>B</given-names></name></person-group><article-title>Dimers and multimers of monoclonal IgG1 exhibit higher in vitro binding affinities to Fcgamma receptors</article-title><source>MAbs</source><year>2009</year><volume>1</volume><fpage>491</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.4161/mabs.1.5.9631</pub-id><pub-id pub-id-type="pmid">20065648</pub-id><pub-id pub-id-type="pmcid">PMC2759499</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lan</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>K</given-names></name><name name-style="western"><surname>Byrd</surname><given-names>D</given-names></name><name name-style="western"><surname>Hu</surname><given-names>N</given-names></name><name name-style="western"><surname>Amet</surname><given-names>T</given-names></name><name name-style="western"><surname>Shepherd</surname><given-names>N</given-names></name><name name-style="western"><surname>Desai</surname><given-names>M</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>S</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Q</given-names></name></person-group><article-title>Provirus activation plus CD59 blockage triggers antibody-dependent complement-mediated lysis of latently HIV-1-infected cells</article-title><source>J Immunol</source><year>2014</year><volume>193</volume><fpage>3577</fpage><lpage>3589</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1303030</pub-id><pub-id pub-id-type="pmid">25149467</pub-id><pub-id pub-id-type="pmcid">PMC4170029</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sips</surname><given-names>M</given-names></name><name name-style="western"><surname>Krykbaeva</surname><given-names>M</given-names></name><name name-style="western"><surname>Diefenbach</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Ghebremichael</surname><given-names>M</given-names></name><name name-style="western"><surname>Bowman</surname><given-names>BA</given-names></name><name name-style="western"><surname>Dugast</surname><given-names>AS</given-names></name><name name-style="western"><surname>Boesch</surname><given-names>AW</given-names></name><name name-style="western"><surname>Streeck</surname><given-names>H</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>DS</given-names></name><name name-style="western"><surname>Ackerman</surname><given-names>ME</given-names></name><etal/></person-group><article-title>Fc receptor-mediated phagocytosis in tissues as a potent mechanism for preventive and therapeutic HIV vaccine strategies</article-title><source>Mucosal Immunol</source><year>2016</year><volume>9</volume><fpage>1584</fpage><lpage>1595</lpage><pub-id pub-id-type="doi">10.1038/mi.2016.12</pub-id><pub-id pub-id-type="pmid">26883728</pub-id><pub-id pub-id-type="pmcid">PMC4988947</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forthal</surname><given-names>DN</given-names></name><name name-style="western"><surname>Landucci</surname><given-names>G</given-names></name><name name-style="western"><surname>Ding</surname><given-names>H</given-names></name><name name-style="western"><surname>Kappes</surname><given-names>JC</given-names></name><name name-style="western"><surname>Wang</surname><given-names>A</given-names></name><name name-style="western"><surname>Thung</surname><given-names>I</given-names></name><name name-style="western"><surname>Phan</surname><given-names>T</given-names></name></person-group><article-title>IgG2 inhibits HIV-1 internalization by monocytes, and IgG subclass binding is affected by gp120 glycosylation</article-title><source>AIDS</source><year>2011</year><volume>25</volume><fpage>2099</fpage><lpage>2104</lpage><pub-id pub-id-type="doi">10.1097/QAD.0b013e32834b64bd</pub-id><pub-id pub-id-type="pmid">21832933</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ana-Sosa-Batiz</surname><given-names>F</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>AP</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Center</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Rerks-Ngarm</surname><given-names>S</given-names></name><name name-style="western"><surname>Pitisuttithum</surname><given-names>P</given-names></name><name name-style="western"><surname>Nitayaphan</surname><given-names>S</given-names></name><name name-style="western"><surname>Kaewkungwal</surname><given-names>J</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JH</given-names></name><name name-style="western"><surname>Michael</surname><given-names>NL</given-names></name><etal/></person-group><article-title>HIV-specific antibody-dependent phagocytosis matures during HIV infection</article-title><source>Immunol Cell Biol</source><year>2014</year><volume>92</volume><fpage>679</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.1038/icb.2014.42</pub-id><pub-id pub-id-type="pmid">24913323</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmad</surname><given-names>A</given-names></name><name name-style="western"><surname>Morisset</surname><given-names>R</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>R</given-names></name><name name-style="western"><surname>Menezes</surname><given-names>J</given-names></name></person-group><article-title>Evidence for a defect of antibody-dependent cellular cytotoxic (ADCC) effector function and anti-HIV gp120/41-specific ADCC-mediating antibody titres in HIV-infected individuals</article-title><source>J Acquir Immune Defic Syndr</source><year>1994</year><volume>7</volume><fpage>428</fpage><lpage>437</lpage><pub-id pub-id-type="pmid">7908983</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gomez-Roman</surname><given-names>VR</given-names></name><name name-style="western"><surname>Florese</surname><given-names>RH</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Peng</surname><given-names>B</given-names></name><name name-style="western"><surname>Venzon</surname><given-names>D</given-names></name><name name-style="western"><surname>Aldrich</surname><given-names>K</given-names></name><name name-style="western"><surname>Robert-Guroff</surname><given-names>M</given-names></name></person-group><article-title>A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity</article-title><source>J Immunol Methods</source><year>2006</year><volume>308</volume><fpage>53</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/j.jim.2005.09.018</pub-id><pub-id pub-id-type="pmid">16343526</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pollara</surname><given-names>J</given-names></name><name name-style="western"><surname>Hart</surname><given-names>L</given-names></name><name name-style="western"><surname>Brewer</surname><given-names>F</given-names></name><name name-style="western"><surname>Pickeral</surname><given-names>J</given-names></name><name name-style="western"><surname>Packard</surname><given-names>BZ</given-names></name><name name-style="western"><surname>Hoxie</surname><given-names>JA</given-names></name><name name-style="western"><surname>Komoriya</surname><given-names>A</given-names></name><name name-style="western"><surname>Ochsenbauer</surname><given-names>C</given-names></name><name name-style="western"><surname>Kappes</surname><given-names>JC</given-names></name><name name-style="western"><surname>Roederer</surname><given-names>M</given-names></name><etal/></person-group><article-title>High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses</article-title><source>Cytometry A</source><year>2011</year><volume>79</volume><fpage>603</fpage><lpage>612</lpage><pub-id pub-id-type="doi">10.1002/cyto.a.21084</pub-id><pub-id pub-id-type="pmid">21735545</pub-id><pub-id pub-id-type="pmcid">PMC3692008</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alpert</surname><given-names>MD</given-names></name><name name-style="western"><surname>Heyer</surname><given-names>LN</given-names></name><name name-style="western"><surname>Williams</surname><given-names>DE</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>JD</given-names></name><name name-style="western"><surname>Greenough</surname><given-names>T</given-names></name><name name-style="western"><surname>Allhorn</surname><given-names>M</given-names></name><name name-style="western"><surname>Evans</surname><given-names>DT</given-names></name></person-group><article-title>A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays</article-title><source>J Virol</source><year>2012</year><volume>86</volume><fpage>12039</fpage><lpage>12052</lpage><pub-id pub-id-type="doi">10.1128/JVI.01650-12</pub-id><pub-id pub-id-type="pmid">22933282</pub-id><pub-id pub-id-type="pmcid">PMC3486484</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Pazgier</surname><given-names>M</given-names></name><name name-style="western"><surname>Sajadi</surname><given-names>MM</given-names></name><name name-style="western"><surname>Kamin-Lewis</surname><given-names>R</given-names></name><name name-style="western"><surname>Al-Darmarki</surname><given-names>S</given-names></name><name name-style="western"><surname>Flinko</surname><given-names>R</given-names></name><name name-style="western"><surname>Lovo</surname><given-names>E</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>JE</given-names></name><name name-style="western"><surname>Seaman</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding</article-title><source>Proc Natl Acad Sci U S A</source><year>2013</year><volume>110</volume><fpage>E69</fpage><lpage>E78</lpage><pub-id pub-id-type="doi">10.1073/pnas.1217609110</pub-id><pub-id pub-id-type="pmid">23237851</pub-id><pub-id pub-id-type="pmcid">PMC3538257</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richard</surname><given-names>J</given-names></name><name name-style="western"><surname>Veillette</surname><given-names>M</given-names></name><name name-style="western"><surname>Brassard</surname><given-names>N</given-names></name><name name-style="western"><surname>Iyer</surname><given-names>SS</given-names></name><name name-style="western"><surname>Roger</surname><given-names>M</given-names></name><name name-style="western"><surname>Martin</surname><given-names>L</given-names></name><name name-style="western"><surname>Pazgier</surname><given-names>M</given-names></name><name name-style="western"><surname>Schon</surname><given-names>A</given-names></name><name name-style="western"><surname>Freire</surname><given-names>E</given-names></name><name name-style="western"><surname>Routy</surname><given-names>JP</given-names></name><etal/></person-group><article-title>CD4 mimetics sensitize HIV-1-infected cells to ADCC</article-title><source>Proc Natl Acad Sci U S A</source><year>2015</year><volume>112</volume><fpage>E2687</fpage><lpage>E2694</lpage><pub-id pub-id-type="doi">10.1073/pnas.1506755112</pub-id><pub-id pub-id-type="pmid">25941367</pub-id><pub-id pub-id-type="pmcid">PMC4443331</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>AW</given-names></name><name name-style="western"><surname>Navis</surname><given-names>M</given-names></name><name name-style="western"><surname>Isitman</surname><given-names>G</given-names></name><name name-style="western"><surname>Wren</surname><given-names>L</given-names></name><name name-style="western"><surname>Silvers</surname><given-names>J</given-names></name><name name-style="western"><surname>Amin</surname><given-names>J</given-names></name><name name-style="western"><surname>Kent</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Stratov</surname><given-names>I</given-names></name></person-group><article-title>Activation of NK cells by ADCC antibodies and HIV disease progression</article-title><source>J Acquir Immune Defic Syndr</source><year>2011</year><volume>58</volume><fpage>127</fpage><pub-id pub-id-type="doi">10.1097/QAI.0b013e31822c62b9</pub-id><pub-id pub-id-type="pmid">21792067</pub-id><pub-id pub-id-type="pmcid">PMC3175260</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>